Document:

Employment Agreement with Adam Goldenberg,dated April 6,2004

 EXHIBIT 10.33 
  
 April 6, 2004 
  
 Mr. Adam Goldenberg 
 456 33rd Street 
 Manhattan Beach, CA 90266 
  
 Re:        Employment Agreement with eCommerce Transactions LLC 
  
 Dear Adam: 
  
 On behalf of eCommerce Transactions LLC (the “Company”), I am pleased to offer you
employment as the President of Performance Marketing Group, a division of the Company, on the terms and conditions set forth in this letter agreement (this “Agreement”). You may accept this Agreement by signing and returning a copy of this
Agreement to the Company as provided below. 
  
 1. Term of Employment. Your
employment under this Agreement shall commence as of February 1, 2004 (“Start Date”) and continue until January 31, 2006, or until such other date on which it is terminated sooner by you or the Company or to which it may be extended by
both you and the Company in a signed writing (the “Separation Date”). Your employment under this Agreement is terminable at will by you or the Company at any time (for any reason or for no reason) subject to the provisions of Section 3.

  
 2. Position and Duties. During the term of this Agreement, the Company
shall employ you as the President of the Performance Marketing Group (“PMG”), a division of the Company, and you shall report to eUniverse, Inc., the Managing Member of the Company (“EUNI”). Your duties shall include the duties
EUNI may delegate to you from time to time consistent with duties assigned to a head of a division of a company of comparable size and with a similar business as the Company. You agree, beginning February 1, 2004 and until the Separation Date, to
commit substantially all of your working time, attention and efforts to the position on a full-time basis. This Agreement is personal to you and you may not assign or delegate any of your rights or obligations hereunder without first obtaining the
written consent of the Company.  
  
 3. Compensation and Benefits.
In consideration for your services to the Company during the time period in which this Agreement is effective, you shall receive the following compensation and benefits from the Company: 
  
 (a) Base Salary. The Company shall pay you an annual base salary at the rate of one hundred seventy-five thousand
dollars ($175,000) per year to be paid in installments according to the Company’s regular payroll policy. The Company shall withhold and deduct all applicable federal and state income and employment and disability taxes from your base salary as
required by applicable laws. 

 April 6, 2004 
  Page
 2
 
  
 (b) Annual
Incentive. The Company shall pay you a bonus equal to six percent (6%) of PMG Net Income (defined below) on an annual basis (the “Annual Incentive”). The Annual Incentive shall be paid in quarterly installments, within forty-five days
from the end of each fiscal quarter based on PMG Net Income for such quarter, with the payment for the fourth quarter of the Company’s fiscal year (ending March 31) to be made within ninety (90) days from the end of such fiscal year and to be
calculated by subtracting (i) the amount of Annual Incentive already paid for the fiscal year to date, from (ii) six percent (6%) of PMG Net Income for such fiscal year. Notwithstanding the above, your Annual Incentive for fiscal year 2004 (ending
March 31, 2004) shall be based on PMG Net Income for the quarter ended December 31, 2003 (“Q304”) and the quarter ending March 31, 2004 (“Q404”), with payment of the portion of the Annual Incentive related to Q304 to be made upon
execution of this Agreement, and payment of the portion of the Annual Incentive related to Q404 to be made within ninety (90) days from the end of fiscal year 2004 and to be calculated by subtracting (i) the amount of Annual Incentive already paid
for Q304, from (ii) six percent (6%) of PMG Net Income for the six (6) months ending March 31, 2004. For purposes of this Section 3(b), PMG Net Income shall mean the net income of the ePMG and Telemarketing (RMS) divisions of the Company determined
by the Company in good faith consistent with the Company’s then applicable practices for determining divisional net income, with adjustment for the following pro forma items: (i) allocation of Company and EUNI corporate overhead in the amount
of $187,500 per quarter, (ii) inter-company revenues and expenses determined in consultation with Company and EUNI business unit, division and subsidiary heads, and (iii) the Annual Incentive to the extent not already reflected in divisional net
income. 
  
 (c) Stock Option. On January 29, 2004, the
Board of Directors of EUNI authorized and approved the issuance to you of a nonqualified option to purchase up to 200,000 shares of EUNI common stock under and pursuant to EUNI’s 1999 Stock Award Plan (the “Plan”) and as more fully
described in the Notice of Grant attached hereto as Exhibit A (the “Option”). 
  
 (d) Section 401(k) Plan and Other Benefits. As an employee of the Company, you shall be eligible to participate in EUNI’s 401(k) Plan, subject to the terms of that plan. You shall also be eligible to
receive such other benefits or rights as may be provided under any employee benefit plans provided by the Company to its executives that are now or hereafter will be in effect, including participation in life, medical, disability and dental
insurance plans, and subject in each instance to the terms of such plans. 
  
 (e) Vacation and Sick Leave. You shall be entitled to accrue up to three (3) weeks of paid vacation each year of employment under this Agreement plus sick leave on the same basis as all other executives of the
Company in accordance with the terms and conditions of the vacation and sick leave policies of the Company. 

 April 6, 2004 
  Page
 3
 
  
 (f)
Termination Payments and Benefits. 
  
 (1) Termination for
Cause or Termination for Other than Good Reason. In the event that your employment with the Company is terminated by the Company for “Cause” (as defined below) or is terminated by you for reasons other than “Good Reason” (as
defined below) then you shall be entitled to payment of your accrued but unpaid salary and vacation pay through the date of the termination of your employment plus any accrued but unpaid Annual Incentive payments. 
  
 (2) Termination Without Cause or for Good Reason or Termination Due to
Death or Disability. In the event that your employment as the President of PMG is terminated by the Company without Cause, is terminated by you due to a Good Reason or is terminated due to your death or Disability, then you or your estate (if
applicable), in addition to the payments described in Section 3(f)(1) above and provided that you (unless you are deceased) execute an effective release with terms substantially as set forth in the attached Exhibit B, shall be entitled to
payment of (i) twelve (12) months of Base Salary, or (ii) your Base Salary though January 31, 2006, whichever is greater. 
  
 (f) Definitions. 
  
 As used in this Agreement, the following terms shall have the meanings set forth below: 
  
 (1) “Cause” shall mean: 
  
 (i) your failure (other than due to Disability) to materially comply with written Company policies generally applicable to
Company executives or employees or any directive of EUNI that is reasonably achievable, that is not inconsistent with your position or the fulfillment of your fiduciary duties and that is not otherwise prohibited by law or established public policy,
subject to notice and 30 day cure period to the extent curable; 
  
 (ii) your engagement in willful misconduct against the Company that is materially injurious to the Company; 
  
 (iii) your engagement in any activity that is a conflict of interest or competitive with the Company, other than any action not taken in bad faith and
which is promptly remedied by you upon notice by the Company; 
  
 (iv) your engaging in any act of fraud or dishonesty against the Company or any of its Affiliates or any material breach of federal or state securities or commodities laws or regulations; 
  
 (v) your engaging in an act of assault or other acts of violence in the
workplace; 

 April 6, 2004 
  Page
 4
 
  
 (vi) your
harassment of any individual in the workplace based on age, gender or other protected status or class or violation of any policy of the Company regarding harassment (subject to investigation by an independent third party of such harassment claim);
or 
  
 (vii) your conviction, guilty plea or plea of nolo
contendre for any felony charge. 
  
 (2) “Disability” shall mean a disability as determined under the Company’s long-term disability plan that prevents you from performing your duties under this Agreement (even with a
reasonable accommodation by the Company) for a period of six months or more. 
  
 (3) “Good Reason” shall mean any one of the following without your consent: 
  

(i) a demotion or any action by the Company which results in diminution of your position, authority, duties or responsibilities (other than any
insubstantial action not taken in bad faith and which is promptly remedied by the Company upon notice by you); 
  
 (ii) requirement that you report to work more than 60 miles from the Company’s existing headquarters (not including normal business travel required
of your position); 
  
 (iii) a reduction in your base salary or
benefits (unless, in the case of a reduction in benefits only, such reduction in benefits applies to all officers of the Company); 
  
 (iv) a material breach by the Company of its obligations hereunder which is not cured within thirty (30) days following written notice to the Company by
you; or 
  
 (v) any failure by a successor to the Company to
assume and agree to perform the Company’s obligations hereunder. 
  
 4.
Employment and Post Termination Covenants. By accepting the terms of this Agreement and as a condition for the termination payments and benefits contemplated by Section 3(f)(2), you hereby agree to the following covenants in addition to any
obligations you may have by law and make the following representations: 
  
 (a) Confidentiality. You acknowledge that, in connection with your employment by the Company, you will have access to trade secrets of the Company and other information and materials which the Company desires
to keep confidential, including customer lists, supplier lists, financial statements, business records and data, marketing and business plans, and information and materials relating to the Company’s services, products, methods of operation, key
personnel, proprietary software and other proprietary intellectual property and information disclosed to the Company of third parties to which the Company owes a duty of nondisclosure 

 April 6, 2004 
  Page
 5
 
  
 (collectively, the
“Confidential Information”); provided, however, that Confidential Information does not include information which (i) is or becomes publicly known other than as a result of your actions in violation of this Agreement; (ii) is or becomes
available to you from a source (other than the Company) that you reasonably believe is not prohibited from disclosing such information to you by a contractual or fiduciary obligation to the Company, (iii) has been made available by the Company,
directly or indirectly, to a non-affiliated third party without obligation of confidentiality; or (iv) you are obligated to produce as a result of a court order or pursuant to governmental action or proceeding, provided that you give the Company
prompt written notice of such requirement prior to such disclosure and assistance in obtaining an order protecting such Confidential Information from public disclosure. You covenant and agree that, both during and after the term of your employment
with the Company, you will keep secret all Confidential Information and will not disclose, reveal, divulge or otherwise make known any Confidential Information to any person (other than the Company or its employees or agents in the course of
performing you duties hereunder) or use any Confidential Information for your own account or for the benefit of any other individual or entity, except with the prior written consent of the Company. 
  
 (b) Ownership of Intellectual Property. You agree that all inventions,
copyrightable material, software, formulas, trademarks, trade secrets and the like which are developed or conceived by you in the course of your employment by the Company or on the Company’s time or property (collectively, the
“Intellectual Property”) shall be disclosed promptly to the Company and the Company shall own all right, title and interest in and to the Intellectual Property. The parties expressly agree that any and all of the Intellectual Property
developed by the Employee shall be considered works made-for-hire for the Company pursuant to the United States Copyright Act of 1976, as amended from time to time. In order to ensure that the Company shall own all right, title and interest in and
to the Intellectual Property in the event that any of the Intellectual Property is not deemed a work made-for-hire (as defined in the Copyright Act of 1976) and in any other event, you hereby sell and assign all right, title and interest in and to
all such Intellectual Property to the Company, and you covenant and agree to affix to the Intellectual Property appropriate legends and copyright notices indicating the Company’s ownership of all Intellectual Property and all underlying
documentation to the extent reasonably appropriate, and shall execute such instruments of transfer, assignment, conveyance or confirmation as the Company reasonably considers necessary to transfer, confirm, vest, perfect, maintain or defend the
Company’s right, title and interest in and to the Intellectual Property throughout the world. Your obligation under this Section 4(b) to assign to the Company inventions created or conceived by you shall not apply to an invention that you
developed entirely on your own time without using the Company’s equipment, supplies, facilities, or trade secret information, provided that those inventions (1) do not or did not relate directly, at the time of conception or reduction to
practice of the invention, to the Company’s business as conducted at such time or actual or demonstrably anticipated research or development of the Company; and (2) do not or did not result from any work performed by you for the Company.

 April 6, 2004 
  Page
 6
 
  
 (c)
Non-Solicitation. You agree for a period ending no sooner than (i) one year following the Separation Date or (ii) the date of the last receipt of any payments by you under this Agreement, whichever is later, that you shall not solicit the
services or employment of the employees of the Company or any of its affiliates and you shall not divert clients or customers of the Company or its affiliates to their disadvantage; provided that (i) general advertisements not specifically directed
at employees of the Company or its affiliates shall not constitute solicitation for purposes of this clause (c) and (ii) this clause (c) shall not prohibit you from hiring employees of the Company or its affiliates who first approach you seeking
employment. 
  
 (d) Non-Competition. You agree not to
compete directly or indirectly as a principal, partner, shareholder, limited liability company member, agent, officer, directors, employee, consultant or in any other capacity, with any current or future business of the Company during the period of
your employment with the Company and during the post-employment period during which you are being paid compensation by the Company; provided that this clause (d) shall not prohibit you from acquiring securities representing less than 5% of the
voting interests of any entity (so long as you are not involved in the management of such entity). 
  
 (e) Authorization To Work for the Company. You represent that you are legally authorized to work in the United States and that your employment with
the Company shall not constitute a violation of any contractual or other legal obligation you may have to another entity or employer. 
  
 5. Business Expenses. You shall be entitled to reimbursement by the Company for such customary, ordinary and necessary business expenses as are incurred by you in
the performance of your duties and activities associated with promoting or maintaining the business of the Company. All expenses as described in this paragraph shall be reimbursed only upon presentation by you of such documentation as may be
reasonably necessary to substantiate that all such expenses were incurred in the performance of his duties in accordance with the Company’s policies 
  
 6. Return Of Company Property. On the Separation Date or as earlier requested by the Company, you agree to return to the Company all Company documents (and all
copies thereof) and other Company property in your possession or control, including, but not limited to, Company files, correspondence, memos, notebooks, notes, drawings, records, business plans and forecasts, financial information, specifications,
computer-recorded information, tangible property and equipment, credit cards, entry cards, identification badges and keys; and any materials of any kind that contain or embody any proprietary or confidential information of the Company (and all
reproductions thereof in whole or in part) (collectively, the “Company Property”). You agree to conduct a good faith and diligent search of your belongings in advance of the aforementioned deadline to ensure your compliance with the
provisions of this Section 6. 
  
 7. Binding on Successors. This Agreement
shall be binding upon the Company and any entity which is a successor by merger, acquisition, consolidation or otherwise to the business 

 April 6, 2004 
  Page
 7
 
  
 formerly carried on by the
Company, or an affiliate of any such entity, and becomes your employer by reason of (or as the direct result of) any direct or indirect sale or other disposition of the Company or substantially all of the assets of the business currently carried on
by the Company, without regard to whether or not such person actively adopts this letter agreement. 
  
 8. Arbitration. You agree that any future disputes between you and the Company (the “parties”) including but not limited to disputes arising out of or related to this Agreement and Release of Claims,
shall be resolved by binding arbitration except where the law specifically forbids the use of arbitration as a final and binding remedy, or where section 8(g) below specifically allows a different remedy. 
  
 (a) The complainant shall provide the other party a written statement of the
claim identifying any supporting witnesses or documents and the relief requested. 
  
 (b) The respondent shall furnish a statement of the relief, if any, that it is willing to provide, and identifying supporting witnesses or documents. If the matter is not resolved, the parties agree to submit their
dispute to a non-binding mediation paid for by the Company, provided, however, that if the amount in dispute is $50,000 or less, this step may be waived at the election of either party. 
  
 (c) If the matter is not resolved, the parties agree that the dispute shall be resolved by binding arbitration according to
the California Code of Civil Procedure, including the provisions of Section 1283.05, pertaining to discovery. 
  
 (d) The arbitrator shall have the authority to determine whether the conduct complained of in section 8(a) violates the complainant’s rights and, if
so, to grant any relief authorized by law; subject to the exclusions of section (g) below. The arbitrator shall not have the authority to modify, change or refuse to enforce any lawful term of this Agreement and Release of Claims. 
  
 (e) The Company shall bear the costs of the arbitration. If the Company
prevails, you shall pay any litigation costs of the Company to the same extent as if the matter had been heard in a court of general jurisdiction. Each party shall pay its own attorneys’ fees, unless the arbitrator orders otherwise, pursuant to
applicable law. 

 (f) Arbitration shall be the exclusive final remedy for any dispute between the parties, such as disputes
involving claims for discrimination or harassment (such as claims under the Fair Employment and Housing Act, Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, or the Age Discrimination in Employment Act), wrongful
termination, breach of contract, breach of public policy, physical or mental harm or distress or any other disputes, and the parties agree that no dispute shall be submitted to arbitration where the complainant has not complied with the preliminary
steps provided for in sections (a) and (b) above. 
  
 (g) The
parties agree that the arbitration award shall be enforceable in any court having jurisdiction to enforce this Agreement and Release of Claims, so long as the arbitrator’s findings of fact are supported by substantial evidence on the whole and
the arbitrator has not made errors of law; however, either party may bring an action in a court of competent jurisdiction, regarding or related to matters involving the Company’s confidential, proprietary or trade secret information, or
regarding or related to inventions that you may claim to have developed prior to or after joining the Company, seeking preliminary injunctive relief in court to preserve the status quo or prevent irreparable injury before the matter can be heard in
arbitration. 
  
 (h) The arbitration shall be held in the city of
Los Angeles, California, unless the parties mutually agree to a different location for the arbitration. 
  
 9. Miscellaneous. 
  
 (a)
This Agreement constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to the terms and conditions of your employment with the Company and your anticipated termination of employment.
It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations and any other written or oral statements
concerning your rights to any compensation, equity or benefits from the Company, its predecessors or successors in interest. Notwithstanding the foregoing, that certain Stock Option Agreement by and between you and EUNI dated as of October 6, 2000,
shall remain in full force and effect. 
  
 (b) Subject to the
mandatory arbitration provided in Section 8 above, jurisdiction and venue in any action to enforce any arbitration award or to enjoin any action that violates the terms of this Agreement shall be in the Superior Court of the County of Los Angeles or
the U.S. District Court for the Central District of California. 
  
 (c) This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company. This Agreement shall bind the heirs, personal representatives, successors and assigns of both you and the
Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination 

 shall not affect any other provision of this Agreement and the provision in question shall be modified by the court so as
to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible. Headings and subheadings in this Agreement are solely for convenience and do not constitute terms of this Agreement. 
  
 (d) This Agreement may be signed in counterparts and the counterparts taken
together shall constitute one agreement. Facsimile signatures shall be deemed as effective as original signatures. 
  
 (e) This Agreement shall be deemed to have been entered into and shall be construed and enforced in accordance with the laws of the State of California as
applied to contracts made and to be performed entirely within California. 
  
 If
this Agreement is acceptable to you, please sign below and return the original, fully executed Agreement to Chris Lipp, General Counsel and Corporate Secretary of EUNI. A copy of the Agreement is also being provided to you for your records.

  
 On behalf of EUNI and the Company, we look forward to your future
contributions to the Company. 
  
 Sincerely, 
  
 ECOMMERCE TRANSACTIONS LLC 
  

			
		
	By:	 	         /s/ Richard Rosenblatt

	 	 	     Richard Rosenblatt, Chief Executive Officer
     eUniverse, Inc., Managing Member

  
 AGREED AND ACCEPTED:

  

					
			
	     /s/ Adam Goldenberg
	 	 	 	     4-7-04

	 Adam Goldenberg
	 	 	 	 DateExclusive License Agreement

 EXHIBIT 10.1 
  
 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such
omissions. 
  
 EXCLUSIVE LICENSE AGREEMENT 
  
 between 
  
 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 
  
 and 
  
 SALMEDIX, INC. 
  
 for 
  

			
		
	 UC Case No. 1999-238
	  	Sensitization of Chronic Lymphocytic Leukemia Cells To Chemotherapeutic Agents By Etodolac Enantiomers
		
	 UC Case No. 1992-283
	  	Method for Selective Methionine Starvation of Malignant Cells In Mammals
		
	 UC Case No. 1992-383
	  	Method for Detection of Methylthioadenosine Phosphorylase Deficiency in Mammalian Cells
		
	 UC Case No. 1996-036
	  	Biochemically Selective Treatment of MTAP-Deficient Cancer
		
	 UC Case No. 1997-128
	  	New Anti-Cancer Drugs
		
	 UC Case No. 2000-343
	  	Assay For Agents That Induce Chemokinesis
		
	 UC Case No. 2000-470
	  	Inhibition of p53 Induced Stress Response
		
	 UC Case No. 2001-096
	  	Treatment of Atherosclerosis and Alzheimer’s Disease with R-Etodolac
		
	 UC Case No. 2001-278
	  	Embryonic G-Coupled Protein Receptors
		
	 UC Case No. 2001-399
	  	Inhibitors of Signal Transduction and Their Use in Malignant, Proliferative and Inflammatory Disease
		
	 UC Case No. 2001-504
	  	Treatment of Osteoarthritis and Macular Degeneration Agonists of WNT-Frizzled Signaling
		
	 UC Case No. 2001-505
	  	Treatment of Osteoarthritis and Macular Degeneration Agonists of WNT-Frizzled Signaling

  

 TABLE OF CONTENTS 
  

					
	 Article No.

	 	 Title

	  	Page

		
	 BACKGROUND
	  	1
	 1.
	 	 DEFINITIONS
	  	3
	 2.
	 	 LICENSE GRANT
	  	8
	 3.
	 	 SUBLICENSES
	  	9
	 4.
	 	 PAYMENT TERMS
	  	11
	 5.
	 	 LICENSE ISSUE FEE
	  	12
	 6.
	 	 LICENSE MAINTENANCE FEE
	  	12
	 7.
	 	 EARNED ROYALTIES AND MINIMUM ANNUAL ROYALTIES
	  	13
	 8.
	 	 MILESTONE PAYMENTS
	  	14
	 9.
	 	 DUE DILIGENCE
	  	15
	 10.
	 	 PROGRESS AND ROYALTY REPORTS
	  	17
	 11.
	 	 BOOKS AND RECORDS
	  	18
	 12.
	 	 LIFE OF THE AGREEMENT
	  	19
	 13.
	 	 TERMINATION BY THE REGENTS
	  	19
	 14.
	 	 TERMINATION BY LICENSEE
	  	20
	 15.
	 	 DISPOSITION OF LICENSED PRODUCT ON HAND UPON TERMINATION
	  	20
	 16.
	 	 USE OF NAMES AND TRADEMARKS
	  	20
	 17.
	 	 LIMITED WARRANTY
	  	21
	 18.
	 	 PATENT PROSECUTION AND MAINTENANCE
	  	22
	 19.
	 	 PATENT MARKING
	  	23
	 20.
	 	 PATENT INFRINGEMENT
	  	23
	 21.
	 	 INDEMNIFICATION
	  	24
	 22.
	 	 NOTICES
	  	25
	 23.
	 	 ASSIGNABILITY
	  	26
	 24.
	 	 NO WAIVER
	  	26
	 25.
	 	 FAILURE TO PERFORM
	  	26
	 26.
	 	 GOVERNING LAWS
	  	26
	 27.
	 	 PREFERENCE FOR U.S. INDUSTRY
	  	27
	 28.
	 	 GOVERNMENT APPROVAL OR REGISTRATION
	  	27
	 29.
	 	 EXPORT CONTROL LAWS
	  	27
	 30.
	 	 SECRECY
	  	27
	 31.
	 	 MISCELLANEOUS
	  	29

  
 EXHIBIT A 
  
 EXHIBIT B 
  
 EXHIBIT C 
  
 EXHIBIT D 
  

 UC Case No(s). 1999-238, 1992-283, 1992-383, 1996-036, 1997-128, 2000-343, 2000-470, 2001-096, 2001-278, 2001-399,
2001-504 and 2001-505 
  
 EXCLUSIVE LICENSE AGREEMENT 

 
 This exclusive license agreement (“Agreement”) is made effective this
21th day of September, 2001 (“Effective Date”), between The Regents of the University of California, a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland,
California 94607-5200 (“The Regents”), and Salmedix, Inc., a Delaware corporation, having a principal place of business at 4330 La Jolla Village Drive, Suite 250, San Diego, California 92122 (“Licensee”). 
  
 BACKGROUND 
  
 A. Certain inventions, generally characterized as Inventions were made in the course of research at the University of
California, San Diego: 
  

					
	 Invention Title

	  	UC Case No.

	  	 Inventors

			
	Sensitization of Chronic Lymphocytic Leukemia Cells to Chemotherapeutic Agents by Etodolac Enantiomers	  	1999-238	  	Dr. Howard B. Cottam, Dr. Lorenzo M. Leoni, Dr. Dennis A. Carson and. Dr. Soichi Adachi
			
	Method For Selective Methionine Starvation Of Malignant Cells In Mammals	  	1992-283	  	Dr. Tsutomu Nobori, Dr. Howard B. Cottam and Dr. Dennis A. Carson
			
	Method for Detection of Methylthioadenosine Phosphorylase Deficiency in Mammalian Cells	  	1992-383	  	Dr. Tsutomu Nobori, Dr. Dennis A. Carson and Kenji Takabayashi of Ciba-Geigy, Ltd.
			
	Biochemically Selective Treatment of MTAP-Deficient Cancer	  	1996-036	  	Dr. Dennis A. Carson, Dr. Carlos J. Carrera, Dr. Howard B. Cottam and Dr. Tsutomu Nobori
			
	New Anti-Cancer Drugs	  	1997-128	  	Dr. Dennis A. Carson, Dr. Hsien C. Shih and Dr. Howard B. Cottam
			
	Assay For Agents That Induce Chemokinesis	  	2000-343	  	Dr. Dennis A. Carson, Dr. Lorenzo M. Leoni and Dr. Howard B. Cottam
			
	Inhibition of p53 Induced Stress Response	  	2000-470	  	Dr. Dennis A. Carson, Dr. Howard B. Cottam and Dr. Lorenzo M. Leoni
			
	Treatment of Atherosclerosis and Alzheimer’s Disease with R-Etodolac	  	2001-096	  	Dr. Dennis A. Carson and Dr. Lorenzo M. Leoni
			
	Embryonic G-Coupled Protein Receptors	  	2001-278	  	Dr. Dennis A. Carson, Dr. Maripat Corr, Dr. Chae-Seo Rhee, Dr. Lorenzo M. Leoni and Dr. Malini Sen

  

 1 

					
	 Invention Title

	  	UC Case No.

	  	 Inventors

			
	Inhibitors of Signal Transduction and Their Use in Malignant, Proliferative and Inflammatory Disease	  	2001-399	  	Dr. Dennis A. Carson, Dr. Howard B. Cottam, Dr. Lorenzo M. Leoni and Dr. Sylvie Barcheecha
			
	Treatment of Osteoarthritis and Macular Degeneration Agonists of WNT-Frizzled Signaling	  	2001-504	  	Dr. Dennis A. Carson
			
	Treatment of Osteoarthritis and Macular Degeneration Agonists of WNT-Frizzled Signaling	  	2001-505	  	Dr. Dennis A. Carson

  
 (collectively
“Inventions”), respectively are covered by Regents’ Patent Rights as defined below. 
  
 B. The development of the Inventions was sponsored in part by The National Institutes of Health and, as a consequence, this license is subject to
overriding obligations to the United States (“U.S.”) Federal Government under 35 U.S.C. §§ 200-212 and applicable regulations including a non-exclusive, non-transferable, irrevocable, paid up license to practice or have practiced
the Inventions for or on behalf of the U.S. Government throughout the world. 
  
 C. The development of UC Case No. 1992-283 was sponsored in part by the American Cancer Society (“ACS”) which does not obtain any rights to the invention. In accordance with the July 30, 1998, standing
exception to the ACS patent policy, The Regents is obligated to include specific diligence milestone provisions in the license of any inventions or intellectual property developed under ACS funding to obligate the licensee to commercialize the
technology in a diligent manner. 
  
 D. The development of UC Case
Nos. 1992-283, 1992-383 and 1997-128 were sponsored in party by CIBA-GEIGY Ltd., which has waived its rights to the invention in a letter to The Regents dated May 14, 1996, a copy of which is attached hereto as Exhibit A. 
  
 E. Dr. Carlos Carrera is currently an employee of the Veterans Administration
Medical Center and The Regents. He may not have been an employee of the Veterans Administration Medical Center during the time when Regents’ Patent Rights in UC Case No. 1996-036 was conceived and reduced to practice, and Dr. Carerra’s
licensing officer is in the process of determining his employment status as it relates to UC Case No. 1996-036. If Dr. Carrera does have an obligation to the Veterans Administration Medical Center in relation to UC Case No. 1996-036, then in
accordance with the policy of the U.S. Department of Veterans Affairs (“VA”), Dr. Carrera will need to report the Invention (UC Case No. 1996-036) to the VA for a determination of rights. It is possible thereafter that the VA will decide
that the U.S. Government should retain its right, title and interest in and to the Invention. Dr. Carrera will then assign his right, title and interest in and to the Invention (UC Case No. 1996-036) jointly to the U.S. Government and The Regents.

  

 2 

 F. The VA and The Regents entered into a Cooperative Technology Administration Agreement (“VA/UC
Agreement”) under which the VA authorizes The Regents to have the exclusive right to prepare, file, prosecute and maintain patent applications and patents covering inventions in which both parties have an interest and the exclusive right to
negotiate, execute and administer agreements for the commercialization of such inventions. A copy of the VA/UC Agreement is attached to this license as Exhibit B. If the VA does have an ownership interest in UC Case No. 1996-036, then this license
will be amended to include the obligations required in the VA/UC Agreement. 
  
 G. Licensee has evaluated the Inventions under a Secrecy Agreement with The Regents (UC Control No. 2001-20-0437) with an effective date of March 5, 2001, and a second Secrecy Agreement (UC Control No. 2001-20-0393)
with an effective date of January 25, 2001. 
  
 H. Licensee is
sponsoring research in the laboratory of Dr. Howard Cottam. 
  
 I.
Licensee proposes to sponsor research in the laboratory of Dr. Maripat Corr. 
  
 J. Licensee wishes to obtain rights from The Regents for the exclusive commercial development, use and sale of products from the Inventions where available, and The Regents is willing to grant those rights where
available so that the Inventions may be developed to their fullest and the benefits enjoyed by the general public. 
  
 K. Licensee is a “small business firm” as defined in 15 U.S.C. § 632. 
  
 L. Both parties recognize and agree that royalties due under this Agreement on products and methods will be paid by Licensee
on both pending patent applications (to the extent provided herein) and issued patents licensed under this Agreement. 
  
 - - oo 0 oo - - 
  
 In view of the foregoing, the parties agree: 
  

	1.	DEFINITIONS 

  
 1.1 “Affiliate” means any corporation or other business entity in which Licensee owns or controls, directly or indirectly, at least *** of the outstanding stock or other voting rights entitled to elect
directors or in which Licensee is owned or controlled directly or indirectly by at least *** of the outstanding stock or other voting rights entitled to elect directors; but in any country where the local law does not permit foreign equity
participation of at least *** then an “Affiliate” includes any company in which Licensee owns or controls, or is owned or controlled by, directly or indirectly, the maximum percentage of outstanding stock or voting rights permitted by
local law. 
  
 1.2 “Human Healthcare Field of Use” means
use for human healthcare. 
  

	***	Material has been omitted pursuant to a request for confidential treatment. 

  
  

 3 

 1.3 “Licensed Method” means any method that is covered by or claimed in Regents’ Patent
Rights, or the use of which would constitute, but for the license granted to Licensee under this Agreement, an infringement of any unexpired claim of a patent or pending claim of a patent application included in Regents’ Patent Rights, or that
is identified from use of, covered by, utilizes or is developed from Regents’ Technology Rights. 
  
 1.4 “Licensed Product” means any product that is covered by or claimed in Regents’ Patent Rights, or that is identified from use of,
covered by, utilizes or is developed from, Regents’ Technology Rights; that is used in a manner requiring the performance of the Licensed Method; that is produced by the Licensed Method or that the manufacture, use or sale of which would be an
infringement, but for the license granted to Licensee pursuant to this Agreement, of an unexpired claim of a patent or pending claim of a patent application included in Regents’ Patent Rights. This definition of Licensed Product also includes a
service either used by Licensee, an Affiliate or sublicensee or provided by Licensee, an Affiliate or sublicensee to its customers when such service requires the use of Licensed Product or performance of Licensed Method. Additionally, for the
avoidance of doubt, if such product is a component of a larger unit such as a kit, composition of matter or combination, then such kit, composition of matter or combination is deemed to be the Licensed Product for purposes of this definition.

  
 1.5 “Type I Therapeutic Licensed Product” means a
therapeutic Licensed Product in the Human Healthcare Field of Use covered by or claimed in Regents’ Patent Rights wherein the therapeutic Licensed Product is covered by composition of matter claims. 
  
 1.6 “Type II Therapeutic Licensed Product” means a therapeutic
Licensed Product in the Human Healthcare Field of Use covered by or claimed in Regents’ Patent Rights wherein the therapeutic Licensed Product is not covered by compositions of matter claims but is covered by method of use claims. 

 
 1.7 “Diagnostic Licensed Product in the Human Healthcare Field of
Use” means a diagnostic and/or prognostic Licensed Product in the Human Healthcare Field of Use covered by or claimed in Regents’ Patent Rights. 
  
 1.8 “Combination Product” means any product which is a Licensed Product and contains or uses a Combination Product Component. 
  
 1.9 “Combination Product Component” means one or more product(s) or
processe(s) that: 
  

	 	1.9.1 	is contained within or used in a Licensed Product; 

  

	 	1.9.2 	is not itself a Licensed Product; 

  

	 	1.9.3 	 after removal of Combination Product Component from each Licensed Product containing or using Combination Product Component, the manufacture, having manufactured,
use, sale, offer for sale or importation of each resulting product 

  

 4 

	 	 
would be an infringement, but for the license granted to Licensee pursuant to this Agreement, of the same unexpired claims of patents and pending claims of
patent applications included in Regents’ Patent Rights as the Licensed Product containing or using it; 

  

	 	1.9.4 	is sold separately, apart from the Combination Product, by Licensee, an Affiliate or sublicensee; 

  

	 	1.9.5 	does not function together with one or more other parts of the Licensed Product that is not a Combination Product Component so as to produce the intended result for which the
Licensed Product is sold; and 

  

	 	1.9.6 	the addition of which to the Licensed Product containing or using the Combination Product Component creates a Licensed Product with a higher market price than the Licensed Product
without the Combination Product included. 

  
 1.10
“Net Sales” means the total of the *** from the Final Sale of Licensed Product to an independent, unaffiliated third party or Licensed Method performed by Licensee, an Affiliate or a sublicensee, less the sum of the following actual and
customary deductions where applicable: *** Final Sale means the sale which is the last act of infringement of Regents’ Patent Rights within the control of Licensee or, an Affiliate, or sublicensee, regardless of whether Licensee or, an
Affiliate, or sublicensee, had control over prior infringing acts. For purposes of calculating Net Sales, any distribution or transfer among Licensee or, an Affiliate, or sublicensee, for end use by Licensee or, an Affiliate, or sublicensee, (which
event is the last act of infringement of Regents’ Patent Rights) will be considered a Final Sale at the price normally charged to independent, unaffiliated third parties. For a Combination Product, Net Sales shall be calculated as follows:

  

	 	1.10.1 	In the event that the Licensed Product is sold as part of a Combination Product, the Net Sales of the Licensed Product, for the purposes of determining royalty payments, shall be
determined by multiplying the Net Sales (as defined in this section) of the Combination Product by the fraction, *** where A is the average sale price of the Licensed Product when sold separately in finished form, and B is the average sale price of
the other product(s) sold separately in finished form. 

  

	***	Material has been omitted pursuant to a request for confidential treatment. 

  
  

 5 

	 	1.10.2 	In the event that the average sale price of the other product(s) can be determined but the average sale price of the Licensed Product cannot be determined, Net Sales for purposes of
determining royalty payments shall be calculated by multiplying the Net Sales of the Combination Product by the following formula: *** where B is the average sale price of the other product(s) when sold separately in finished form and C is the
average selling price of the Combination Product. 

  

	 	1.10.3 	Notwithstanding Paragraphs 1.10.1 and 1.10.2, in no event shall Net Sales for a Combination Product be less than *** of Net Sales of the Licensed Product that is a Combination
Product. 

  
 1.11 “Non US Major Market
Country” means the United Kingdom, Germany, France, Italy, Canada, or Japan. 
  
 1.12 “Materials” means the chemical and biological material produced or developed by Drs. Carson, Cottam, Leoni, and Corr or by third parties on behalf of Drs. Carson, Cottam, Leoni, and Corr, at the
University of California, San Diego in existence at the time of execution by this Agreement and listed in Exhibit C. 
  
 1.13 “Biological Materials” means: 
  

	 	1.13.1 	the Materials, their progeny, mutations, hybrids, derivatives or unmodified functional subunits derived therefrom by Licensee; 

  

	 	1.13.2 	any material which incorporates any of the Materials, their progeny, mutations, hybrids, derivatives or unmodified functional subunits; 

  

	 	1.13.3 	material contained in or produced by any of the Materials, including secreted or encoded products obtained by Licensee from any Materials; or 

  

	 	1.13.4 	any material similar to a material described in 1.13.3 above, produced by Licensee using chemical synthesis or any other method based on use of the Materials.

  
 1.14 “Regents’ Technology Rights”
means: 
  

	 	1.14.1 	The Regents’ property rights in the Biological Material and 

  

	 	1.14.2 	The Regents’ property rights in the items listed in Exhibit C. 

  

	***	Material has been omitted pursuant to a request for confidential treatment. 

  
  

 6 

 1.15 “Regents’ Patent Rights” means The Regents’ interest in the following:

  

					
	 UC Case Number

	  	U.S. Application Number or U.S. Patent Number

	 	Filing or Issue Date

	 1999-238-1
	  	***	 	***
	 1999-238-1
	  	***	 	***
	 1999-238-2
	  	***	 	***
	 1999-238-3
	  	***	 	***
	 1992-283-1
	  	5,571,510	 	11/05/1996
	 1992-283-2
	  	***	 	***
	 1992-283-3
	  	6,210,917	 	4/03/2001
	 1992-283-4
	  	***	 	***
	 1992-383-1
	  	***	 	***
	 1992-383-1
	  	***	 	***
	 1992-383-2
	  	***	 	***
	 1992-383-3
	  	5,942,393	 	8/24/1999
	 1992-383-4
	  	***	 	***
	 1992-383-5
	  	***	 	***
	 1992-383-6
	  	***	 	***
	 1996-036-1
	  	5,840,505	 	11/24/1998
	 1996-036-1
	  	***	 	***
	 1996-036-2
	  	***	 	***
	 1997-128-1
	  	***	 	***
	 1997-128-2
	  	6,162,810	 	12/19/2000
	 1997-128-2
	  	***	 	***
	 1997-128-2
	  	***	 	***
	 2000-343-1
	  	***	 	***
	 2000-343-2
	  	***	 	***
	 2000-470
	  	***	 	***
	 2001-096
	  	***	 	***
	 2001-278
	  	***	 	***
	 2001-399
	  	***	 	***
	 2001-504
	  	***	 	***
	 2001-505
	  	***	 	***

  

	***	Material has been omitted pursuant to a request for confidential treatment. 

  

 7 

 and continuing applications thereof including divisions and substitutions but excluding
continuation-in-part applications (except to the extent, however, that claims in the continuation-in-part applications are entitled to the priority filing date of the parent application referenced above); any patents on said applications including
reissues, reexaminations and extensions; and any corresponding foreign applications or patents. 
  
 1.16 “Alanosine Case(s)” means UC Case Numbers 1992-283, 1992-383 and 1996-036. 
  
 1.17 “Etodolac Case(s)” means UC Case Numbers 1999-238, 2000-343 and 2001-096. 
  
 1.18 “IBT Cases” means UC Case Numbers 2000-470 and 2001-399.

  
 1.19 “Indanocine Case” means UC Case Number
1997-128. 
  
 1.20 “Embryonic G-Coupled Protein Receptor
Case(s)” means UC Case Numbers 2001-278, 2001-504 and 2001-505. 
  
 1.21 “Sublicense Fees” means the total cash license fees received by Licensee as a result of any sublicense of its rights under this Agreement. Sublicense Fees shall not include any amounts received as support for research and
development activities (not substantially in excess of reasonable and customary rates), money derived from debt financing, bona fide equity investments in Licensee at market value, reimbursement for patent costs, or earned royalty on Net Sales.

  

	2.	LICENSE GRANT 

  
 2.1 Subject to the limitations set forth in this Agreement, The Regents grants to Licensee a world-wide license under Regents’ Patent Rights to make,
have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method, to the extent pennitted by law. 
  
 2.2 Except as otherwise provided in this Agreement, the license granted in Paragraph 2.1 is exclusive for the life of this Agreement. 
  
 2.3 The license granted in Paragraphs 2.1 and 2.2, is subject to all the
applicable provisions of any license to the U.S. Government executed by The Regents and is subject to the overriding obligations to the U.S. Government under 35 U.S.C. §§200-212 and applicable governmental implementing regulations.

  
 2.4 The license granted in Paragraphs 2.1 and 2.2, is limited
to methods and products that are within the Human Healthcare Field of Use. For all other methods and products, Licensee has no license under this Agreement. 
  
 2.5 Subject to the limitations set forth in this Agreement, The Regents grants to Licensee a non-exclusive right to make and use Regents’ Technology
Rights in the development of Licensed Products and for no other purpose. 
  

 8 

 2.6 Drs. Carson, Cottam, Leoni, and Corr shall transfer the Materials to Licensee in such quantities and
at such times as set forth in Exhibit C together with protocols for handling the Materials. Such Materials which are biological in nature will be viable and propagatable by biologists with a generally accepted level of skill in the art. The Regents
reserves the right to use the Inventions, Materials, Biological Materials and associated technology for educational and research purposes including publication of research results and sharing such research results, the Inventions, Materials,
Biological Materials and associated technology with other educational and non-profit institutions for their use of similar scope. 
  
 2.7 Title to the tangible material comprising the Biological Material is owned by The Regents and is not transferred to Licensee under this Agreement
except as necessary to permit the sale of Licensed Products by Licensee, Affiliates and sublicensees. 
  

	3.	SUBLICENSES 

  
 3.1 The Regents also grants to Licensee the right to issue sublicenses to Regents’ Patent Rights to third parties to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed
Method, as long as Licensee has current exclusive rights thereto under this Agreement. To the extent applicable, sublicenses must include all of the rights of and obligations due to The Regents (and, if applicable, the U.S. Government) contained in
this Agreement. 
  
 3.2 Licensee shall promptly provide The
Regents with a copy of each sublicense issued, collect and guarantee payment of all payments due The Regents from sublicensees and summarize and deliver all reports due The Regents from sublicensees. 
  
 3.3 Upon termination of this Agreement for any reason (but not upon
expiration of this Agreement pursuant to Paragraph 12.1), The Regents, at its sole reasonable discretion, shall determine whether Licensee shall terminate or assign to The Regents any and all sublicenses, provided that The Regents will not assume
any obligations of the sublicense that extend beyond the duties and obligations of The Regents that are contained in this Agreement. At any time during the term of this Agreement, upon Licensee’s or any sublicensee’s request, The Regents
agrees to meet and confer with Licensee and such sublicensee (or potential sublicensee) to discuss what assurances The Regents might give to the sublicensee that the sublicense to any subject group of cases (e.g. Alanosine Cases) sublicensed will
not be terminated upon the termination of this Agreement. To the extent The Regents is willing to give such assurances, The Regents agrees that it shall enter into a written agreement with Licensee and such sublicensee setting forth The
Regents’ assurances and The Regents’ agreement not to require termination of the sublicense. 
  

 9 

 3.4 The Regents shall receive: 
  

	 	3.4.1 	ten (10%) percent of Sublicense Fees; and 

  

	 	3.4.2 	an earned royalty as provided for in Paragraph 7.1 on Net Sales by sublicensees; provided however that in the event that a sublicense agreement contains a royalty provision that
would pay Licensee a royalty that is less than twice the earned royalty owed The Regents as provided for in Paragraph 7.1, then Licensee may retain *** of such royalty and the Regents will be paid *** of such royalty. Notwithstanding the foregoing,
in no event shall the earned royalty due to The Regents on Net Sales by sublicensees be less than *** of the earned royalty amount that would otherwise have been due to The Regents as provided for in Paragraph 7.1. 

  
 3.5 If The Regents (as represented by the actual knowledge of the licensing
professional responsible for administration of this case) or a third party discovers and notifies that licensing professional that inventions related to Regents’ Patent Rights for which Licensee was granted an exclusive license are useful for
an application covered by the Human Healthcare Field of Use but for which Licensed Products have not been developed or are not currently under development by Licensee, The Regents, as represented by the Office of Technology Transfer, may give
written notice to the Licensee. 
  
 3.6 Licensee shall have *** to
give The Regents written notice stating whether Licensee elects to develop Licensed Products for such application. 
  
 3.7 If Licensee elects to develop and commercialize the proposed Licensed Products for the new application, Licensee shall submit a Progress Report every
six months to The Regents outlining the Licensee’s development and commercialization efforts for such new application. 
  
 3.8 If Licensee elects not to develop and commercialize the proposed Licensed Products for use in the new application, The Regents may seek (a) third
party(ies) to develop and commercialize the proposed Licensed Products for the new application. If The Regents is successful in finding such third party, it shall refer such third party to Licensee. If the third party requests a sublicense under
this Agreement, then the Licensee shall report the request to The Regents within thirty (30) days from the date of such written request. If the request results in a sublicense, then Licensee shall report it to The Regents. 
  
 3.9 If the Licensee refuses to grant a sublicense to such third party, then
within thirty (30) days after such refusal the Licensee shall submit to The Regents a report specifying the license terms proposed by the third party and a written justification for the Licensee’s refusal to grant the proposed sublicense. If
The Regents, at its sole reasonable discretion, determines that the terms of the sublicense proposed by the third party are reasonable under the circumstances, then The Regents shall have the right to grant to the third party a license to make, have
made, use, sell, offer for sale and import products for 
  

	***	Material has been omitted pursuant to a request for confidential treatment. 

  

 10 

 
use in the Human Healthcare Field of Use on terms no less favorable to The Regents as the terms last proposed to Licensee by the third party providing
royalty rates are at least equal to those paid by Licensee, subject to the following limitation: 
  

	 	3.9.1 	that The Regents may not license rights necessary to develop any product with the same active pharmaceutical ingredient and/or for an indication competitive with a Licensed Product
which has been commercialized or is under active commercial development by Licensee. 

  
 3.10 For avoidance of doubt, the Regents will not have the right, under Paragraph 3.9, to grant a license to any product or material developed
independently by Licensee which is not covered by Regents’ Patent Rights or Regents’ Technology Rights. 
  

	4.	PAYMENT TERMS 

  
 4.1 Paragraphs 1.3, 1.4 and 1.15 define Licensed Method, Licensed Product and Regents’ Patent Rights, so that royalties are payable on products and
methods covered by both pending patent applications and issued patents subject to the terms and conditions of this Agreement. Royalties will accrue on a product-by-product basis in each country for the duration of Regents’ Patent Rights in that
country and are payable to The Regents when Licensed Products are invoiced or if not invoiced, when delivered to a third party. 
  
 4.2 Licensee shall pay to The Regents earned royalties quarterly on or before March 31, June 30, September 30, and December 31 of each calendar year. Each
payment will be for earned royalties accrued within Licensee’s prior calendar quarter. 
  
 4.3 All monies due The Regents are payable in U.S. dollars. Licensee is responsible for all bank transfer charges. When Licensed Product is sold for monies other than U.S. dollars, Licensee shall first determine the
earned royalty in the currency of the country in which Licensed Product was sold and then convert the amount into equivalent U.S. funds, using the exchange rate quoted in The Wall Street Journal on the last business day of the reporting period.

  
 4.4 Royalties earned on sales occurring in any country outside
the U.S. may not be reduced by any taxes, fees or other charges imposed by the government of such country on the payment of royalty income. Notwithstanding the foregoing, all payments made by Licensee in fulfillment of The Regents’ tax
liability in any particular country will be credited against earned royalties or fees due The Regents for that country. 
  
 4.5 If at any time legal restrictions prevent the prompt remittance of royalties by Licensee from any country where a Licensed Product is sold, then
Licensee shall convert the amount owed to The 

  

 11 

 Regents into U.S. funds and shall pay The Regents directly from its U.S. source of funds for as long as
the legal restrictions apply. 
  
 4.6 If any patent or patent
claim within Regents’ Patent Rights is held invalid in a final decision by a court of competent jurisdiction and last resort and from which no appeal has or can be taken, then all obligation to pay royalties based on that patent or claim or any
claim patentably indistinct therefrom will cease as of the date of final decision. Except as set forth in Paragraph 4.7 below, Licensee will not, however, be relieved from paying any royalties that accrued before the final decision or that are based
on another patent or claim not involved in the final decision or that are based on Regents’ Technology Rights. 
  
 4.7 No royalties may be collected or paid on Licensed Product sold to the account of the U.S. Government, or any agency thereof, as provided for in the
license to the U.S. Government. 
  
 4.8 In the event payments,
rebillings or fees are not received by The Regents when due, Licensee shall pay to The Regents interest charges at the lesser of (a) the prime rate quoted by Citibank N.A. plus ***, (b) *** per annum or (c) the maximum rate permitted by law.
Interest is calculated from the date payment was due until actually received by The Regents. 
  

	5.	LICENSE ISSUE FEE 

  
 Licensee shall pay to The Regents a license issue fee of fifty thousand dollars ($50,000) within thirty (30) days of the Effective Date. This fee is
non-refundable, non-cancelable and is not an advance against royalties. 
  

	6.	LICENSE MAINTENANCE FEE 

  
 Licensee shall also pay to The Regents a royalty in the form of a license maintenance fee of twenty-five thousand dollars ($25,000) beginning on the
one-year anniversary of the Effective Date and continuing annually on each anniversary of the Effective Date. The license maintenance fee is due within thirty (30) days of the anniversary of the Effective Date. The license maintenance fee shall not
be due on any anniversary of the Effective Date if on that date Licensee (or any Affiliate or sublicensee) is commercially selling a Licensed Product or practicing a Licensed Method and (a) paying an earned royalty to The Regents on the sales of
that Licensed Product or Licensed Method or (b) paying a minimum annual royalty to The Regents as set forth in Paragraph 7.2 below. In any calendar year in which a milestone payment under Article 8 is due, *** of the annual license maintenance fee
will be creditable against such milestone payment. 

  

	***	Material has been omitted pursuant to a request for confidential treatment. 

  

 12 

	7.	EARNED ROYALTIES AND MINIMUM ANNUAL ROYALTIES 

  
 7.1 Licensee shall also pay to The Regents an earned royalty on Net Sales as follows: (1) *** of the Net Sales of Type I Therapeutic Licensed
Products; (ii) *** of the Net Sales of Type II Therapeutic Licensed Products; (iii) *** of the Net Sales of Diagnostic Licensed Product; and (iv) and *** of the Net Sales of any other Licensed Products and (v) *** of the Net Sales of a Licensed
Product that is not covered by Regents Patent Rights but is identified from use of, covered by, utilizes or is developed from use of Regents’ Technology Rights. 
  
 7.2 Licensee shall pay to The Regents a minimum annual royalty of *** for the life of Regents’ Patent Rights,
beginning with the year of the first commercial sale of any Licensed Product, but no later than December 2011. For the first year of commercial sales, Licensee’s obligation to pay the minimum annual royalty will be pro-rated for the number of
months remaining in that calendar year when commercial sales commence and will be due the following March 31, to allow for crediting of the pro-rated year’s earned royalties. For subsequent years, the minimum annual royalty will be paid to The
Regents by March 31 of each year and will be credited against the earned royalty due for the calendar year in which the minimum payment was made. 
  
 7.3 Licensee shall, however, be entitled to reduce the earned royalty provided for in Paragraph 7.1 in the event that it becomes necessary (either by
order or judgment of any court or otherwise) for Licensee to license patent rights owned by third parties to make, have made, use or sell Licensed Product. Such reduction shall be equal to *** of any payment made to such third party under such
license against up to *** of the amounts payable to The Regents under Paragraph 7.1 above on a going forward basis. Credits with respect to this Paragraph shall be available to Licensee with respect to the full royalty payable pursuant to Paragraph
7.1 and no such credit shall be available with respect to any Combination Product. 
  
 7.4 Royalties payable under this Article will be payable only once with respect to a particular Licensed Product or Licensed Method and will be paid only once regardless of the number of patents, or patent
applications in Regents Patent Rights covering such Licensed Product or Licensed Method. In the event any Licensed Product qualifies as more than one type of Licensed Product under this Agreement, only the highest earned royalty percentage amongst
the relevant types of Licensed Products shall apply. 
  

	***	Material has been omitted pursuant to a request for confidential treatment. 

  
  

 13 

	8.	MILESTONE PAYMENTS 

  
 8.1 Milestone Payments for Type I Therapeutic Licensed Products and Type II Therapeutic Licensed Products covered by a claim within the Regents’
Patent Rights set forth in UC Case No. 1999-238: 
  

	 	8.1.1	*** upon the dosing of a first subject in a large scale human clinical trial conducted in human subjects and intended by Licensee to generate data concerning the safety and efficacy
of such a Therapeutic Licensed Product for the particular medical condition for which it is being studied sufficient to support registration of such a Therapeutic Licensed Product with drug regulatory authorities; and 

  

	 	8.1.2	*** upon filing of the New Drug Application with the United States Food and Drug Administration pursuant to 21 U.S.C. Section 357 and 21 C.F.R. Section 314 for such a Therapeutic
Licensed Product, as such sections are amended or supplemented from time to time; and 

  

	 	8.1.3	*** upon the grant of approval for marketing of such a Therapeutic Licensed Product by the United States Food and Drug Administration; and 

  

	 	8.1.4	*** upon the grant of approval for marketing of such a Therapeutic Licensed Product by the foreign regulatory authority in a Non-US Major Market Country equivalent to the United
States Food and Drug Administration in the United States. 

  
 8.2 Other Licensed Product Milestone Payments: Licensee shall pay to The Regents for each Therapeutic Licensed Product covered by a claim within the Regents’ Patent Rights other than UC Case No. 1999-238: 
  

	 	8.2.1	*** upon filing of the Investigational New Drug Application with the United States Food and Drug Administration for such a Therapeutic Licensed Product. 

  

	 	8.2.2	*** upon the dosing of a first human subject in a large scale human clinical trial conducted in the United States in human subjects and intended by Licensee to generate data
concerning the safety and efficacy of such a Therapeutic Licensed Product for the particular medical condition for 

  

	***	Material has been omitted pursuant to a request for confidential treatment. 

  
  

 14 

 which it is being studied sufficient to support registration of such a Therapeutic Licensed Product with
drug regulatory authorities; and 
  

	 	8.2.3	*** upon filing of the New Drug Application with the United States Food and Drug Administration pursuant to 21 U.S.C. Section 357 and 21 C.F.R. Section 314 for such a Therapeutic
Licensed Product, as such sections are amended or supplemented from time to time; and 

  

	 	8.2.4	*** upon the grant of approval for marketing of such a Therapeutic Licensed Product by the United States Food and Drug Administration; and 

  

	 	8.2.5	*** upon the grant of approval for marketing of such a Therapeutic Licensed Product by the foreign regulatory authority in a Non-US Major Market Country equivalent to the United
States Food and Drug Administration in the United States. 

  
 8.3 Diagnostic Licensed Product payments: For each Diagnostic Licensed Product Licensee shall pay to The Regents: 
  

	 	8.3.1	*** upon the filing of a PMA or 510k or other requests for marketing approval by the United States Food and Drug Administration, as is appropriate for that Diagnostic Licensed
Product; and 

  

	 	8.3.2	*** upon the grant of approval for marketing of such a Diagnostic Licensed Product by the United States Food and Drug Administration; and 

  

	 	8.3.3	*** upon the grant of approval for marketing of such a Diagnostic Licensed Product by the foreign regulatory authority in a Non-US Major Market Country equivalent to the United
States Food and Drug Administration in the United States. 

  
 8.4 For the avoidance of doubt, milestones will be paid once for each therapeutic Licensed Product and once for each Diagnostic Licensed Product. 
  
 8.5 All milestone payments are due to The Regents within thirty (30) days of each milestone event. 
  

	9.	DUE DILIGENCE 

  
 9.1 Licensee, upon execution of this Agreement, shall diligently proceed with the development, manufacture and sale of Licensed Products and shall use
commercially reasonable efforts to 
  

	***	Material has been omitted pursuant to a request for confidential treatment. 

  
  

 15 

 market the same within a reasonable time after execution of this Agreement and in quantities sufficient to meet market
demands. 
  
 9.2 Licensee shall endeavor to obtain all necessary
governmental approvals for the manufacture, use and sale of each Licensed Product. 
  
 9.3 Licensee shall: 
  

											
	 Task

	  	Etodolac Cases
(1999-238, 2000-
343, 2001-096)

	 	Alanosine Cases
(1992-283, 1992-
383, 1996-036,)

	 	Indanocine Case
(1997-128)

	 	Embryonic G-
Coupled Protein
Receptors Cases
(2001-278, 2001-504,
2001-505)

	 	IBT
Cases
(2000-470,
2001-399)

						
	 Select candidate compound for clinical development within _ years of the Effective Date of the Agreement
	  	***	 	***	 	***	 	***	 	***
						
	 Initiate Phase I clinical trials for Licensed Product (first dose in human) within _ years of the Effective Date of the
Agreement
	  	***	 	***	 	***	 	***	 	***
						
	 Begin a pivotal trial for Licensed Product within _ years of the Effective Date of the Agreement
	  	***	 	***	 	***	 	***	 	***
						
	 Submit a request for either US or Non US Major Market Country regulatory approval covering Licensed Product within years from the Effective
Date of this Agreement
	  	***	 	***	 	***	 	***	 	***

  

	 	9.3.1	market each Licensed Product in the U.S. within *** of receiving approval of such Licensed Product from the FDA; and 

	***	Material has been omitted pursuant to a request for confidential treatment. 

  
  

 16 

	 	9.3.2	reasonably fill the market demand for each Licensed Product following commencement of marketing at any time during the exclusive period of this Agreement. 

 
 9.4 If Licensee is unable to perform any of the above provisions then The
Regents will grant Licensee a cure period of *** to perform said provision. If, at the expiration of the cure period, the Licensee is still unable to perform said provision, then The Regents has the right and option to either terminate this
Agreement with respect to the specific patents or patent applications under Regents’ Patent Rights covering a set of cases (that is Etodolac Cases, Alanosine Cases, Indanocine Cases, 1BT Cases, Embryonic G-Coupled Protein Receptors Cases) or
reduce Licensee’s exclusive license to a nonexclusive license with respect to the specific set of cases to which the failure to perform is related. This right, if exercised by The Regents, supersedes the rights granted in Article 2 (License
Grant). 
  
 9.5 In addition to the obligations set forth above,
Licensee shall spend an aggregate of not less than two million dollars ($2,000,000) for the development of all Licensed Products during the first three (3) years of this Agreement. 
  

	10.	PROGRESS AND ROYALTY REPORTS 

  
 10.1 Beginning December 31, 2001, and semi-annually thereafter, Licensee shall submit to The Regents a written progress report covering Licensee’s
(and any Affiliate’s or sublicensee’s) activities related to the development and testing of all Licensed Product and the obtaining of the governmental approvals necessary for marketing. Progress reports are required for each Licensed
Product. 
  
 10.2 Progress reports submitted under Paragraph 10.1
shall include, but are not limited to, the following topics: 
  

	 	10.2.1	summary of work completed; 

  

	 	10.2.2	key scientific discoveries and clinical trial results, including notice of efficacy of each Licensed Product in Phase II, Phase IIb, Phase III or any pivotal trials;

  

	 	10.2.3	summary of work in progress; 

  

	 	10.2.4	current schedule of anticipated events or milestones; 

  

	 	10.2.5	following filing of an NDA with the U.S. FDA, market plans for introduction of Licensed Product; and 

  

	 	10.2.6	a summary of resources (dollar value) spent in the reporting period. 

  

	 	10.2.7	Licensee’s progress in developing any application of The Regents’ Patent Rights elected for commercial development by Licensee pursuant to Paragraph 3.7 of this Agreement.

	***	Material has been omitted pursuant to a request for confidential treatment. 

  

 17 

 10.3 Licensee has a continuing responsibility to keep The Regents informed of the large or small business
entity status (as defined by the U.S. Patent and Trademark Office) of itself and its sublicensees and Affiliates. 
  
 10.4 Licensee shall report to The Regents in its immediately subsequent progress and royalty report the date of first commercial sale of a Licensed
Product in each country. 
  
 10.5 After the first commercial sale
of a Licensed Product anywhere in the world, Licensee shall make quarterly royalty reports to The Regents on or before each March 31 (for the quarter ending December 31), June 30 (for the quarter ending March 31), September 30 (for the quarter
ending June 30) and December 31 (for the quarter ending September 30) of each year. Each royalty report will cover Licensee’s most recently completed calendar quarter and will show: 
  

	 	10.5.1	the gross sales and Net Sales of Licensed Product sold during the most recently completed calendar quarter; 

  

	 	10.5.2	the number of each type of Licensed Product sold; 

  

	 	10.5.3	the royalties, in U.S. dollars, payable with respect to sales of Licensed Product; 

  

	 	10.5.4	the method used to calculate the royalty; 

  

	 	10.5.5	the exchange rates used; and 

  

	 	10.5.6	for each Licensed Product, the specific Regents’ Patent Rights and/or Regents’ Technology Rights identified by UC Case No(s). exercised by Licensee, an Affiliate or
Sublicensee of Licensee in the course of making, having made, using selling offering for sale or importing such Licensed Product 

  
 10.6 If no sales of Licensed Product have been made during any reporting period, then a statement to this effect is required. 
  

	11.	BOOKS AND RECORDS 

  
 11.1 Licensee shall keep accurate books and records showing all Licensed Product manufactured, used and/or sold under the terms of this Agreement. Books
and records must be preserved for at least five (5) years from the date of the royalty payment to which they pertain. 
  
 11.2 All records shall be available during normal business hours for inspection at the expense of The Regents by a Certified Public Accountant selected by
The Regents and reasonably acceptable to Licensee and in compliance with the other terms of this Agreement for the sole purpose of verifying reports and payments no more than one time for each annual period. Such inspector shall not disclose to The
Regents any information other than information relating to the accuracy of reports and payments made under this Agreement or other compliance issues. In the event that any such inspection shows an 

  

 18 

 
under reporting and underpayment in excess of five percent (5%) for any twelve (12) month period, then Licensee shall pay the cost of the audit. 

 

	12.	LIFE OF THE AGREEMENT 

  
 12.1 Unless otherwise terminated by operation of law or by acts of the parties in accordance with the terms of this Agreement, this Agreement will be in
force from the Effective Date until the date of expiration of the last-to-expire patent licensed under this Agreement; or until the last patent application licensed under this Agreement is abandoned and no patent in Regents’ Patent Rights ever
issues. 
  
 12.2 Any termination of this Agreement will not affect
the rights and obligations set forth in the following Articles: 
  

			
	 Article 11
	  	Books and Records
	 Article 15
	  	Disposition of Licensed Product on Hand Upon Termination
	 Article 16
	  	Use of Names and Trademarks
	 Article 21
	  	Indemnification
	 Article 25
	  	Failure to Perform
	 Article 30
	  	Secrecy

  

	13.	TERMINATION BY THE REGENTS 

  
 If Licensee fails to perform or violates any material term of this Agreement, then The Regents may give written notice of default (“Notice of
Default”) to Licensee. If Licensee fails to repair the default within one-hundred twenty (120) days of the effective date of Notice of Default, then The Regents may terminate this Agreement and its licenses by a second written notice
(“Notice of Termination”) provided however, that if the default is related to a due diligence obligation of Licensee under Paragraph 9.3 then The Regents may terminate this Agreement only as provided for in Paragraph 9.4 provided further
that, if Licensee cannot reasonably cure any such default not under Paragraph 9.4 within one hundred twenty (120) days The Regents may but shall not be required to agree to an extension of a reasonable period of time in which Licensee may cure any
such default. If a Notice of Termination is sent to Licensee, then this Agreement will automatically terminate on the effective date of that notice. Such termination will not relieve Licensee of its obligation to pay any fees owing at the time of
termination and will not impair any accrued right of The Regents. These notices are subject to Article 22 (Notices). 
  

 19 

	14.	TERMINATION BY LICENSEE 

  
 14.1 Licensee has the right at any time to terminate this Agreement in whole or as to any portion of Regents’ Patent Rights by giving notice in
writing to The Regents. Such notice of termination will be subject to Article 22 (Notices) and termination of this Agreement will be effective ninety (90) days from the effective date of such notice. 
  
 14.2 Any termination under this Article 14 does not relieve Licensee of any
obligation or liability accrued under this Agreement prior to termination or rescind any payment made to The Regents or anything done by Licensee prior to the time termination becomes effective. Termination does not affect in any manner any rights
of The Regents arising under this Agreement prior to termination. 
  

	15.	DISPOSITION OF LICENSED PRODUCT ON HAND UPON TERMINATION 

  
 Upon termination of this Agreement, Licensee is entitled to dispose of all previously made or partially made Licensed Product, but no more, within a
period of one hundred and twenty (120) days provided that the sale of Licensed Product is subject to the terms of this Agreement, including, but not limited to, the rendering of reports and payment of royalties required under this Agreement.

  

	16.	USE OF NAMES AND TRADEMARKS 

  
 16.1 Nothing contained in this Agreement confers any right to use in advertising, publicity or other promotional activities any name, trade name,
trademark or other designation of either party hereto (including contraction, abbreviation or simulation of any of the foregoing). Unless required by law, the use by Licensee of the name “The Regents of the University of California” or the
name of any campus of the University of California is prohibited. 
  
 16.2 The Regents is free to release to the inventors and senior administrators employed by The Regents the terms and conditions of this Agreement. If such release is made, then The Regents shall give notice of the confidential nature and
shall request that the recipient does not disclose such terms and conditions to others. If a third party inquires whether a license to Regents’ Patent Rights is available, then The Regents may disclose the existence of this Agreement and the
extent of the grant in Article 2 (Life of Patent Exclusive Grant) to such third party, but will not disclose the name of Licensee or any other terms or conditions of this Agreement, except where The Regents is required to release information under
either the California Public Records Act, a governmental audit requirement or other applicable law. 
  
 16.3 Licensee may disclose the existence of this Agreement (including the fact that it contains license grants from The Regents) and the terms and
conditions contained herein to the extent such disclosure is reasonably necessary for the following purposes: (a) conducting clinical trials; (b) making 

  

 20 

 
regulatory filings; (c) complying with applicable governmental regulations; (d) submitting information to sublicensees (potential and actual), consultants
and others having a need to know for the purposes of development, manufacture or marketing of Licensed Product or Licensed Method pursuant to this Agreement, provided that such sublicensees, consultants and others shall also agree to appropriate and
comparable confidentiality and non-use provisions as provided for in Paragraph 30.1.3; (e) to the extent required by applicable law, orders of courts, regulatory authorities or similar bodies having jurisdiction over Licensee; and (f) fund-raising.

  

	17.	LIMITED WARRANTY 

  
 17.1 The Regents warrants to Licensee that it has the lawful right to grant this license. 
  
 17.2 This license and the associated Inventions are provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. THE REGENTS MAKES NO REPRESENTATION OR WARRANTY THAT LICENSED PRODUCT OR LICENSED METHOD WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT. 
  
 17.3 IN NO EVENT WILL EITHER PARTY BE LIABLE FOR ANY INCIDENTAL, SPECIAL OR
CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THIS LICENSE OR THE USE OF THE INVENTIONS OR LICENSED PRODUCT. 
  
 17.4 This Agreement does not: 
  

	 	17.4.1	express or imply a warranty or representation as to the validity or scope of any of Regents’ Patent Rights or Regents’ Technology Rights; 

  

	 	17.4.2	express or imply a warranty or representation that anything made, used, sold, offered for sale or imported or otherwise disposed of under any license granted in this Agreement is or
will be free from infringement of patents of third parties; 

  

	 	17.4.3	obligate The Regents to bring or prosecute actions or suits against third parties for patent infringement except as provided in Article 20 (Patent Infringement);

  

	 	17.4.4	confer by implication, estoppel or otherwise any license or rights under any patents of The Regents other than Regents’ Patent Rights as defined in this Agreement, regardless
of whether those patents are dominant or subordinate to Regents’ Patent Rights; or 

  

	 	17.4.5	obligate The Regents to furnish any know-how not provided in Regents’ Patent Rights or Regents’ Technology Rights. 

  

 21 

	18.	PATENT PROSECUTION AND MAINTENANCE 

  
 18.1 As long as Licensee has paid patent costs as provided for in this Article 18 (Patent Prosecution and Maintenance), The Regents shall diligently
endeavor to prosecute and maintain the U.S. and foreign patents comprising Regents’ Patent Rights using counsel to be chosen by The Regents from The Regents’ list of approved patent counsel after consultation with the Licensee. The
Regents shall regularly provide Licensee with copies of all patent applications filed hereunder and other material submissions and correspondence with the patent offices, in sufficient time to allow for review and comment by Licensee. In addition,
The Regents shall provide Licensee and its patent counsel with an opportunity to consult with The Regents and its patent counsel regarding the filing and contents of any such application, amendment, submission or response, and the advice and
suggestions of Licensee and its patent counsel shall be taken into reasonable consideration by The Regents and its legal counsel in connection with such filing. The Regents shall also provide Licensee with copies of any patentability search reports
made by patent counsel with respect to the Inventions, a copy of each patent application, and each patent that issues thereon. Licensee agrees to keep this documentation confidential. The Regents’ counsel will take instructions only from The
Regents, and all patents and patent applications under this Agreement will be assigned solely to The Regents. 
  
 18.2 The Regents shall use reasonable efforts to amend any patent application to include claims or description or to file in countries reasonably
requested by Licensee to protect the Licensed Products or Licensed Methods. 
  
 18.3 Licensee shall apply for an extension of the term of any patent included within Regents’ Patent Rights if appropriate under the Drug Price Competition and Patent Term Restoration Act of 1984 and/or European,
Japanese and other foreign counterparts of this Law. Licensee shall prepare all documents and The Regents agrees to execute the documents and to take additional action as Licensee reasonably requests in connection therewith. 
  
 18.4 If either party (in the case of The Regents, the Licensing Officer
responsible for administration of this Agreement) receives notice pertaining to infringement or potential infringement of any issued patent included within Regents’ Patent Rights under the Drug Price Competition and Patent Term Restoration Act
of 1984 (and/or foreign counterparts of this Law), then that party shall notify the other party within ten (10) days after receipt of notice of infringement. 
  
 18.5 Licensee shall bear all reasonable costs of preparing, filing, prosecuting and maintaining all U.S. and foreign patent applications contemplated by
this Agreement except for the cost previously reimbursed by prior licensees or optionees, where applicable. Costs billed by The Regents’ counsel will be rebilled to Licensee and are due within thirty (30) days of rebilling by The Regents. These
costs include patent prosecution costs for the Inventions incurred by The Regents prior to the execution of this 

  

 22 

 Agreement and any patent prosecution costs that may be incurred for patentability opinions, re-examination, re-issue,
interferences, oppositions or inventorship determinations, Any such prior prosecution costs not previously reimbursed will be due upon execution of this Agreement and billing by The Regents but in any event shall not be due prior to the date that is
sixty (60) days following the execution of this Agreement, and are at least two hundred five thousand three hundred sixty-seven dollars and forty cents ($205,367.40) as listed in Exhibit D. 
  
 18.6 Licensee may request The Regents to obtain patent protection on the
Inventions in foreign countries if available and if it so desires. Licensee shall notify The Regents of its decision to obtain or maintain foreign patents not less than sixty (60) days prior to the deadline for any payment, filing or action to be
taken in connection therewith. This notice concerning foreign filing must be in writing, must identify the countries desired and must reaffirm Licensee’s obligation to underwrite the costs thereof. The absence of such a notice from Licensee to
The Regents will be considered an election not to obtain or maintain foreign rights. 
  
 18.7 Licensee’s obligation to underwrite and to pay patent prosecution costs will continue for so long as this Agreement remains in effect, but Licensee may terminate its obligations with respect to any given
patent application or patent upon three (3) months’ written notice to The Regents. The Regents will use its best efforts to curtail patent costs when a notice of termination is received from Licensee. The Regents may prosecute and maintain such
application(s) or patent(s) at its sole discretion and expense, but Licensee will have no further right or licenses thereunder. Non-payment of patent costs may be deemed by The Regents as an election by Licensee not to maintain application(s) or
patent(s). 
  
 18.8 The Regents may file, prosecute or maintain
patent applications at its own expense in any country in which Licensee has not elected to file, prosecute or maintain patent applications in accordance with this Article 18 (Patent Prosecution and Maintenance) and those applications and resultant
patents will not be subject to this Agreement. 
  

	19.	PATENT MARKING 

  
 Licensee shall mark all Licensed Product made, used or sold under the terms of this Agreement, or their containers, in accordance with the applicable
patent marking laws. 
  

	20.	PATENT INFRINGEMENT 

  
 20.1 If Licensee learns of the substantial infringement of any patent licensed under this Agreement, then Licensee shall call The Regents’ attention
thereto in writing and provide The Regents with reasonable evidence of infringement. Neither party will notify a third party of the infringement of 
  

 23 

 
any of Regents’ Patent Rights without first obtaining consent of the other party, which consent will not be unreasonably denied. Both parties shall use
their best efforts in cooperation with each other to terminate infringement without litigation. 
  
 20.2 Licensee may request that The Regents take legal action against the infringement of Regents’ Patent Rights. Such request must be in writing and
must include reasonable evidence of infringement and damages to Licensee. If the infringing activity has not abated within ninety (90) days following the effective date of request, then The Regents has the right to: 
  

	 	20.2.1	commence suit on its own account; or 

  

	 	20.2.2	refuse to participate in the suit, and 

  
 The Regents shall give notice of its election in writing to Licensee by the end of the one-hundredth (100th) day after receiving notice of written request
from Licensee. Licensee may thereafter bring suit for patent infringement, at its own expense, if and only if The Regents elects not to commence suit and if the infringement occurred during the period and in a jurisdiction where Licensee had
exclusive rights under this Agreement. If, however, Licensee elects to bring suit in accordance with this Paragraph 20.2, then The Regents may thereafter join that suit at its own expense. Licensee agrees not to bring suit for patent infringement
without following the procedures of this Paragraph, and both parties agree to be bound by an order of a court for patent infringement, patent infringement issues and patent infringement defenses raised through the pendency of such a suit under this
Paragraph 20.2. 
  
 20.3 Legal action, as is decided on, will be
at the expense of the party bringing suit and all damages recovered thereby will belong to the party bringing suit, but legal action brought jointly by The Regents and Licensee and fully participated in by both will be at the joint expense of the
parties and all recoveries will be shared jointly by them in proportion to the share of expense paid by each party. 
  
 20.4 Each party shall cooperate with the other in litigation proceedings instituted hereunder but at the expense of the party bringing suit. Litigation
will be controlled by the party bringing the suit, except that The Regents may be represented by counsel of its choice in any suit brought by Licensee. 
  

	21.	INDEMNIFICATION 

  
 21.1 Licensee shall indemnify, hold harmless and defend The Regents, its officers, employees and agents, the sponsors of the research that led to the
Inventions and the inventors of the patents and patent applications in Regents’ Patent Rights and their employers against any and all claims, suits, losses, liabilities, damages, costs, fees and expenses. resulting from or arising out of
exercise of this license or any sublicense. This indemnification includes, but is not limited to, any product liability. 
  

 24 

 21.2 Licensee, at its sole cost and expense, shall insure its activities in connection with the work
under this Agreement and obtain, keep in force and maintain insurance as follows or an equivalent program of self-insurance. 
  
 21.3 Comprehensive or commercial form general liability insurance (contractual liability included) with limits as follows: 
  

	 	•	Each Occurrence *** 

  

	 	•	Products/Completed Operations Aggregate *** 

  

	 	•	Personal and Advertising Injury *** 

  

	 	•	General Aggregate (commercial form only) *** 

  
 The coverage and limits referred to under the above do not in any way limit the liability of Licensee. Licensee shall furnish The Regents with
certificates of insurance showing compliance with all requirements. Certificates must: 
  

	 	•	Provide for thirty (30) days’ advance written notice to The Regents of any modification adversely affecting The Regents. 

  

	 	•	Indicate that The Regents has been endorsed as an additional Insured under the coverage referred to under the above. 

  

	 	•	Include a provision that the coverage will be primary and will not participate with nor will be excess over any valid and collectable insurance or program of self-insurance carried
or maintained by The Regents. 

  
 21.4 The Regents
shall notify Licensee in writing of any claim or suit brought against The Regents in respect of which The Regents intends to invoke the provisions of this Article 21 (Indemnification). Licensee shall keep The Regents informed on a current basis of
its defense of any claims under this Article 21 (Indemnification). 
  

	22.	NOTICES 

  
 22.1 Any notice or payment required to be given to either party shall be deemed to have been properly given and to be effective as of the date specified below if delivered to the respective address given below or to
another address as designated by written notice given to the other party: 
  

	 	22.1.1	on the date of delivery if delivered in person; 

  

	 	22.1.2	on the date of faxing if delivered by facsimile with confirmed receipt; or 

  

	 	22.1.3	on the date of mailing if mailed by any global express carrier service that requires recipient to sign the documents demonstrating the delivery of such notice or payment.

  

	***	Material has been omitted pursuant to a request for confidential treatment. 

  
  

 25 

			
	 In the case of Licensee:
	  	 Salmedix, Inc.
 4330 La Jolla Village
Drive,
 Suite 250
 San Diego, California 92122
 Attention: Chief Executive Officer

		
	 In the case of The Regents:
	  	 The Regents of the University of California
 Office of
Technology Transfer
 1111 Franklin Street, 5th Floor
 Oakland, CA
94607-5200
 Attention:  Executive Director
                     Research Administration and Technology Transfer

		
	 	  	 RE:    UC Case Nos. 1992-238, 1992-283, 1992-383, 1996-036, 1997-128, 2000-470, 2001-096, 2001-278, 2001-399. 2001-504
and 2001, 505

  

	23.	ASSIGNABILITY 

  
 This Agreement may be assigned by The Regents, but is personal to Licensee and assignable by Licensee only with the written consent of The Regents, which
consent will not be unreasonably withheld; provided, however, that upon written notification to The Regents, Licensee may assign all of its rights and delegate all of its duties hereunder to an Affiliate or to an entity which acquires at least that
portion of its business, patents and properties to which this Agreement relates, or to any corporate successor by way of merger or consolidation, provided that such assignee assumes all of the Licensee’s obligations hereunder. 
  

	24.	NO WAIVER 

  
 No waiver by either party of any default of this Agreement may be deemed a waiver of any subsequent or similar default. 
  

	25.	FAILURE TO PERFORM 

  
 If either party finds it necessary to undertake legal action against the other on account of failure of performance due under this Agreement, then the
prevailing party is entitled to reasonable attorney’s fees in addition to costs and necessary disbursements. 
  

	26.	GOVERNING LAWS 

  
 THIS AGREEMENT WILL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA WITHOUT REGARD TO CONFLICT OF 

  

 26 

 
LAWS OR TO WHICH PARTY DRAFTED PARTICULAR PROVISIONS OF THIS AGREEMENT, but the scope and validity of any patent or patent application will be governed by
the applicable laws of the country of the patent or patent application. Disputes between the parties regarding this Agreement will utilize only trial courts within California for disputes that go to court. 
  

	27.	PREFERENCE FOR U.S. INDUSTRY 

  
 Because this Agreement includes the grant of the exclusive right to use or sell the Inventions in the U.S., Licensee agrees that any products sold in the
U.S. embodying the Inventions or produced through the use thereof will be manufactured substantially in the U.S. 
  

	28.	GOVERNMENT APPROVAL OR REGISTRATION 

  
 Licensee shall notify The Regents if it becomes aware that this Agreement is subject to any U.S. or foreign government reporting or approval requirement.
Licensee shall make all necessary filings and pay all costs including fees, penalties and all other out-of-pocket costs associated with such reporting or approval process. 
  

	29.	EXPORT CONTROL LAWS 

  
 Licensee shall observe all applicable U.S. and foreign laws with respect to the transfer of Licensed Product and related technical data to foreign
countries, including, without limitation, the International Traffic in Arms Regulations (ITAR) and the Export Administration Regulations. 
  

	30.	SECRECY 

  
 30.1 With regard to confidential information (“Data”), which can be oral or written or both, received from The Regents regarding the Inventions, Licensee agrees: 
  

	 	30.1.1	not to use the Data except for the sole purpose of performing under the terms of this Agreement including, without limitation, disclosure to sublicensees); 

 

	 	30.1.2	to safeguard Data against disclosure to others with the same degree of care as it exercises with its own data of a similar nature; 

  

 27 

	 	30.1.3	not to disclose Data to others (except to its employees, agents, consultants or third parties who are bound to Licensee by a like obligation of confidentiality) without the express
written permission of The Regents, except that Licensee is not prevented from using or disclosing any of the Data that: 

  

	 	30.1.3.1 	Licensee can demonstrate by written records was previously known to it; 

  

	 	30.1.3.2 	is now or becomes in the future, public knowledge other than through acts or omissions of Licensee; or 

  

	 	30.1.3.3 	is lawfully obtained by Licensee from sources independent of The Regents; 

  

	 	30.1.3.4 	is required to be disclosed to a governmental entity or agency in connection with seeking any governmental or regulatory approval, or pursuant to the lawful requirement or request
of a governmental entity or agency; and 

  

	 	30.1.4	that the secrecy obligations of Licensee with respect to Data will continue for a period ending five (5) years from the termination date of this Agreement. 

 
 30.2 Upon the termination of this Agreement, Licensee must destroy or
return to The Regents any Data in its possession within thirty (30) days following the effective date of termination. However, Licensee may retain one copy of Data solely for archival purposes, provided that such Data is subject to the
confidentiality provisions set forth in this Article 29 (Secrecy). Within sixty (60) days following termination, Licensee must provide The Regents with a written notice that Data has been returned or destroyed. 
  
 30.3 With regard to Material received by Licensee from The Regents, if any,
Licensee agrees: 
  

	 	30.3.1	not to use Biological Material except for the sole purpose of performing under the terms of this Agreement (including, without limitation, use by sublicensees);

  

	 	30.3.2	not to transfer Biological Material to others (except to its employees, agents or consultants or third parties who are bound to Licensee by like obligations conditioning and
restricting access, use and continued use of Biological Material) without the express written permission of The Regents, except that Licensee is not prevented from transferring Biological Material that: 

  

	 	30.3.2.1 	becomes publicly available other than through acts or omissions of Licensee; or 

  

	 	30.3.2.2 	is lawfully obtained by Licensee from sources independent of The Regents; 

  

	 	30.3.3	to safeguard Biological Material against disclosure and transmission to others with the same degree of care as it exercises with its own biological materials of a similar nature;
and 

  

	 	30.3.4	to destroy all copies of Biological Material at the termination of this Agreement. 

  

 28 

	31.	MISCELLANEOUS 

  
 31.1 The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or
interpretation of this Agreement. 
  
 31.2 This Agreement is not
binding on the parties until it has been signed below on behalf of each party. It is then effective as of the Effective Date. 
  
 31.3 No amendment or modification of this Agreement is valid or binding on the parties unless made in writing and signed on behalf of each party.

  
 31.4 This Agreement embodies the entire understanding of the
parties and supersedes all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof. The Secrecy Agreement (UC Control No. 2001-20-0437) dated March 5, 2001, and
(UC Control No. 2001-20-0393) dated January 25, 2001 are hereby terminated. 
  
 31.5 In case any of the provisions contained in this Agreement is held to be invalid, illegal or unenforceable in any respect, that invalidity, illegality or unenforceability will not affect any other provisions of
this Agreement and this Agreement will be construed as if the invalid, illegal or unenforceable provisions had never been contained in it. 
  
 31.6 This Agreement includes the attached Exhibits A, B, C and D. 
  

31.7 None of the provisions of this Agreement is intended to create any form of joint venture between the parties, rights in third parties or rights
that are enforceable by any third party. 
  
 -remainder of the page
left blank deliberately- 
  

 29 

 31.8 The parties to this Agreement will be excused from any performance required hereunder if such
performance is rendered impossible or unfeasible due to any acts of God, catastrophes, or other major events beyond their reasonable control, including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or
regulations; strikes, lock-outs, or other serious labor disputes; and floods, fires, explosions, or other natural disasters. Either party to this Agreement will have the right to terminate this Agreement upon thirty (30) days prior written notice if
either party is unable to fulfill its obligations under this Agreement due to any of the causes mentioned above provided that such inability to perform continues for a period of six (6) months. Notices will be subject to Article 22 (Notices).

  
 IN WITNESS WHEREOF, both The Regents and Licensee have
executed this Agreement, in duplicate originals, by their respective and duly authorized officers on the day and year written. 
  

									
	 SALMEDIX, INC.
	 	 	 	 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

					
	By:	 	/S/    DAVID S. KABAKOFF	 	 	 	By:	 	/S/    ALAN B. BENNETT
	 	 	
	 	 	 	 	 	

	 	 	(Signature)	 	 	 	 	 	(signature)
					
	 Name:
	 	David S. Kabakoff	 	 	 	 Name:
	 	Alan B. Bennett
	 	 	
	 	 	 	 	 	 
	 	 	(Please Print)	 	 	 	 	 	 
					
	 Title:
	 	President & CEO	 	 	 	 Title:
	 	 Executive Director
 Research Administration and Technology Transfer

	 	 	
	 	 	 	 	 
	 	 	(Please Print)	 	 	 	 	 
					
	 Date:
	 	4/18/01	 	 	 	 Date:
	 	4/17/01
	 	 	
	 	 	 	 	 	

  

									
	 	 	 	 	 APPROVED AS TO LEGAL FORM

					
	 	 	 	 	 	 	 	 	/S/    EDWIN H. BAKER
	 	 	 	 	 	 	 	 	

	 	 	 	 	 	 	 	 	 Edwin H. Baker
 University Counsel
 Office of General Counsel

  

 30 

 EXHIBIT A 
  
 [CIBA LETTERHEAD] 
  
 VIA FEDERAL EXPRESS 
  
 May 29, 1996 
  
 David J. Aston 
 Assistant Director 
 University of California 
 Office of Technology Transfer 
 1320 Harbor Bay Pkwy 
 Suite 150 
 Alameda, CA 94502 
  

	RE:	Patent Costs/Carson Portfolio 

  
 Dear David: 
  
 Enclosed, please find an original of your letter of May 14, 1996, countersigned for Ciba by Dr. Alan J. Main. 
  
 As we agreed, this letter serves to clarify formally that Ciba no longer has rights to the listed cases, and, therefore, is no longer responsible for associated patent
costs incurred after November 3, 1995. 
  
 Thanks again. 
  
 With best regards, 
  

	
	
	/s/    ARNOLD S. RUBIN        
	

	 Arnold S. Rubin, Ph.D.
 Director, Licensing

  

	cc:	A. Main 

	  	H. Nowak (with duplicate original) 

  

 [UNIVERSITY OF CALIFORNIA LETTERHEAD] 
  
 May 14, 1996 
  
 IN DUPLICATE 
  
 Arnold Rubin, Ph.D. 
 Director of Licensing 
 Ciba-Geigy Corporation 
 556 Morris Avenue 
 Summit, NJ 07901 
  

	Re:	Carson Portfolio 

  
 Dear Arnold: 
  
 The purpose of this letter is to
clarify that Ciba has no further rights in the following cases and will no longer be responsible for patent costs incurred after November 3, 1995. Upon request of The Regents, Ciba-Geigy Corporation will assign its interest in the co-owned case UC
92-383. Patent costs for UC 93-268 will be governed by our option agreement. 
  

			
	 UC Case 92-283
	  	Method for Selected Methionine Starvation of Malignant Cells in Mammals
		
	 UC Case 92-383
	  	Method for Detection of Methylthioadenosine Phosphorylase Deficiency in Mammalian Cells
		
	 UC Case 92-296
	  	Allergy Gene Immunotherapy and Cancer Gene Immunotherapy Projects
		
	 UC Case 94-009
	  	Method for Reduction of Endotoxin Contamination of Plasmid Derived DNA
		
	 UC Case 94-029
	  	Compounds for Inhibition of Inflammation and Fibrosis
		
	 UC Case 94-091
	  	Tumor Suppressor Gene and Methods for Detection of Cancer, Monitoring of Tumor Progression and Cancer Treatment
		
	 UC Case 96-114
	  	Non-coding Regions of DNA Expression Vectors Necessary for Gene Immunization

  

 Arnold S. Rubin, Ph.D. 
 May
14, 1996 
 Page 2 
  
 Please indicate your agreement with this by countersigning one original of this letter and returning it to me at your earliest convenience. 
  

	
	Sincerely,
	
	/s/    DAVID J. ASTON        
	

	David J. Aston
	Associate Director

  
 AGREED TO: 
  

			
	CIBA-GEIGY CORPORATION
	
	                        /s/    ALAN
MAIN                    /MJM
	

	 Name:
	 	Alan Main
	 Title:
	 	Senior Vice President, Research
	 Date:
	 	5/29/96

  

 EXHIBIT B 
  
 U.S. DEPARTMENT OF VETERANS AFFAIRS 
  
 AND THE UNIVERSITY OF CALIFORNIA 
  
 COOPERATIVE TECHNOLOGY ADMINISTRATION AGREEMENT 
  
 This Cooperative Technology Administration Agreement (“Agreement”) is made as of this 19th day of May, 2000, by and between the United States
Department of Veterans Affairs (hereinafter referred to as “VA”), as represented by the Technology Transfer Program, Office of Research and Development, having an address at 810 Vermont Avenue N. W., Washington, D. C. 20420, and The
Regents of the University of California, as represented by the Office of Technology Transfer, having an address at 1111 Franklin Street, 5th Floor, Oakland, California 94607-5200 (“University”). 
  
 RECITALS 
  
 Whereas, VA and University through
their employment relationship with certain faculty and staff, through 37 CFR Part 501, and/or through 35 U.S.C. 200-212, as well as state law and implementing policies, have an interest in inventions made by their employees; 
  
 Whereas, VA and University policies promote disclosure of research results for the
public’s use and benefit, as well as to define and protect the rights of inventors, provide for an equitable distribution of the rewards and responsibilities associated with the invention(s), and provide that income from such invention(s) be
used for the purpose of promoting research and education; 
  
 Whereas, pursuant to
their shared objectives, it is the mutual desire of VA and University that their respective interests in such inventions be administered and managed exclusively by University on behalf of both parties in a manner to ensure the timely
commercialization of such inventions and to make their benefits widely available for society’s use and benefit; 
  
 Whereas, VA is authorized to transfer to and to undertake all suitable steps to administer its rights in any such existing or future invention through contract with a
nonprofit organization (including a university) under 35 U.S.C. 202(e) (to the maximum extent permitted by law), 35 U.S.C. 207(a)(3), or 15 U.S.C. 3710a; 
  
 Now, therefore, the parties hereto agree as follows: 
  

	1.	DEFINITIONS 

  

	 	1.1	“Dual Appointment Personnel (DAP)” means any person who is employed by and has entered into and signed an employment or patent agreement with both VA and University.

  

	 	1.2	 “Patent Rights” means all United States patent applications and patents and corresponding patent applications and patents filed in countries other than
the United States that are assigned to VA and University, including any reissues, extensions, substitutions, divisions, continuations, and continuation-in-part applications (only to the 

  

	 	 
extent, however, that claims in the continuations-in-part applications are entitled to the priority filing date of the parent patent application) based on
the subject matter claimed in or covered by a Subject Invention. 

  

	 	1.3	“Property Rights” means all personal property rights covering the tangible personal property in biological materials directly associated with any Subject Invention.

  

	 	1.4	“Made” in relation to any Subject Invention means the conception or first actual reduction to practice of such Subject Invention. 

  

	 	1.5	“Subject Invention” means Patent Rights and/or related Property Rights covering any existing or future disclosed invention in which both parties have an interest under
their various policies, that is made either by a DAP or at least one inventor from each party, and that is not a Disclaimed Invention. 

  

	 	1.6	“Disclaimed Invention” means any Subject Invention for which University declines to pursue patenting, license or commercialization activities under Section 2.2 of this
Agreement. 

  

	 	1.7	“License Agreement” means any executed agreement entered into by University under this Agreement that grants Licensee the right to make, use, sell, offer for sale, or
import products covered by or claimed by the Subject Invention being licensed under such agreement or otherwise deals with administration of the Subject Invention, such as option or secrecy agreements. 

  

	 	1.8	“Licensee” means any party, not including the United States Government, that enters into a License Agreement with University. 

  

	 	1.9	“Government” means the Government of the United States of America. 

  

	 	1.10	“Fiscal Year” means July 1 through June 30. 

  

	 	1.11	“Gross Revenues” means consideration received by University from the licensing of any Subject Invention, but not including consideration in the form of research funding or
other research support. 

  

	 	1.12	“Net Revenues” means Gross Revenues, less any prior contractual obligations to third party research supporters or joint owners, then less Administrative Fee, Expenses,
Inventors Share, and Research Share for each Subject Invention. 

  

	 	1.13	“Inventors Share” means those revenues due under the applicable University of California policy to named inventors for each Subject Invention. 

  

	 	1.14	“Research Share” means those revenues to be allocated directly for research purposes, if any, under the applicable University of California Patent Policy for each Subject
Invention. 

  

	 	1.15	 “Expenses” means legal and other direct expenses incurred by University (that are not otherwise reimbursed from a third party) for patenting, protecting
and preserving U.S. and foreign patent, copyright and related property rights, maintaining patents and such 

  

 2 

	 	 
other costs, taxes, or reimbursements as may be necessary or required by law for each Subject Invention. 

  

	 	1.16	“Administrative Fee” means *** fee of Gross Revenues retained by University in consideration of University’s commercialization efforts for each Subject Invention.

  

	 	1.17	“UC Site” means the campus or U.S. Department of Energy Laboratory managed by University at which a Subject Invention is made. 

  

	 	1.18	“Pooled Amount” means Net Revenues aggregated by UC site cumulatively over time beginning the effective date of this Agreement for all of that UC Site’s Subject
Inventions. 

  

	2.	PATENT PROSECUTION AND PROTECTION 

  

	 	2.1	Disclosure. The parties agree to promptly and in confidence report to the other party each Subject Invention. VA agrees to provide to University a copy of its Determination of
Rights letter to inventors regarding any potential Subject Invention. 

  

	 	2.2	Disclaimed Inventions. University shall notify VA in writing of any individual Subject Invention for which the University declines to pursue patenting, licensing or
commercialization activities, and as of the date of such notice, that invention shall no longer be considered a Subject Invention under this Agreement. 

  

	 	2.3	VA authorizes University to have the exclusive right to prepare, file, prosecute, and maintain patent application(s) and patents covering any Subject Invention. University shall
promptly provide to VA, upon request, all serial numbers and filing dates, together with copies of all such applications, including, on request copies of all Patent Office Actions, responses, and all other Patent Office communications. In addition,
University shall be granted Power of Attorney for all such patent applications. 

  

	 	2.4	University shall make an election with respect to foreign filing including in which countries foreign filing will be done prior to the election, within ten (10) months of any United
States filing. If any foreign patent applications are filed, University shall promptly, upon request, provide to VA all serial numbers and filing dates together with copies of all such foreign patent applications, including on request, copies of all
Patent Office Actions. 

  

	 	2.5	University shall promptly record assignments of domestic patent rights covering a Subject Invention in the United States Patent and Trademark Office and shall promptly provide VA
with a copy of each recorded assignment with respect to VA. 

  

	 	2.6	Notwithstanding any other provision of this Agreement, University shall not abandon the prosecution of any patent application including provisional patent applications (except for
purposes of filing continuation application(s)) or the maintenance of any patent for a Subject Invention without prior written notice to VA. Upon receiving such written notice, VA may, at its sole option and expense, take over the prosecution of any
such patent application, or the maintenance of any such patent, and such invention shall no longer be considered a Subject Invention under this Agreement. 

  

	***	Material has been omitted pursuant to a request for confidential treatment. 

  

 3 

	 	2.7	University may decide to bail Property Rights as a more efficient commercialization method than patenting. If University so decides, then University will follow the guidelines
issued by the U.S. National Institutes of Health on such commercialization approach. 

  

	3.	LICENSING 

  

	 	3.1	VA authorizes University to have the exclusive right to negotiate, execute, and administer any License Agreement. VA shall not license to any third parties any Subject Invention
unless this Agreement is terminated in accordance with Article 7 (Termination) and there are no License Agreements in effect or under negotiation. VA also agrees to not pre-commit any Subject Inventions or future inventions that would be Subject
Inventions under this Agreement to a commercial research sponsor or other entity through prior agreements made by VA foundations or others. 

  

	 	3.2	VA authorizes University to have the sole right to diligently seek a Licensee and negotiate and enter into License Agreements for the commercial development of any Subject Invention
and to administer all such License Agreements for the mutual benefit of the parties and in the public interest. 

  

	 	3.3	University shall have the final authority to enter into negotiations and execute License Agreements. In accordance with Section 5.2, University shall provide VA with a copy of all
executed License Agreements. VA shall keep these documents and related documentation confidential, unless such disclosure is required by law, except that VA may disclose the existence of any License Agreement, but only to the extent of the granting
clause. VA will not disclose the names of the Licensee or any other terms contained in the License Agreement unless such disclosure is required under law. 

  

	 	3.4	University agrees to not enter into a License Agreement for commercial development of Subject Invention with a company who is identified on the current list of companies debarred
from covered transactions as provided, and updated from time to time, by the VA. 

  

	 	3.5	Any respective License Agreement will include provisions that address the following: 

  

	 	3.5.1 	The License Agreement will be subject to the overriding obligations to the U.S. Government, including those set forth in 35 U.S.C. §200-212 or 15 U.S.C. 3710a, and applicable
governmental implementing regulations, whichever may be appropriate. 

  

	 	3.5.2 	For a License Agreement granting an exclusive right to use or sell the Subject Invention in the United States, Licensee knowledges that any patent products embodying the Subject
Invention or produced through the use thereof will be manufactured substantially in the United States. 

  

	 	3.5.3 	The Government shall have the nonexclusive, nontransferable, irrevocable, royalty-free, paid-up right to practice or have practiced the Subject Invention throughout the world by or
on behalf of the Government and on behalf of any foreign government or international organization pursuant to any existing or future treaty or agreement to which the Government is a signatory. 

  

 4 

	 	3.5.4 	The Government shall retain the right to require University to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive license to use the invention in the
applicant’s licensed field of use on terms that are reasonable under the circumstances; or, if University fails to grant such a license, to grant the license itself The Government may exercise its rights retained herein only in exceptional
circumstances and only if the Government determines that (i) the action is necessary to meet health or safety needs that are not reasonably satisfied by University; (ii) the action is necessary to meet requirements for public use specified by
Federal regulations, and such requirements are not reasonably satisfied by University; or (iii) University has failed to comply with an agreement containing provisions described in 35 U.S.C. 204 or 15 U.S.C. 3710a(c)(4)(B), whichever is appropriate.

  

	4.	REVENUES 

  

	 	4.1	Inventor Share. University shall be solely responsible for calculating and distributing Inventor Share pursuant to University of California policy. Inventor Share will be
distributed equally among the named inventors unless mutually agreed in writing by all inventors. 

  

	 	4.2	Research Share. University shall be solely responsible for calculating and distributing Research Share. The Research Share will be pro-rated in proportion to the number of sole
University, sole VA and DAP employee inventors. For financial calculation purposes under this section, any DAP will be considered to be *** VA and *** University, regardless of actual employment percentages. 

  

	 	Example: 	For an invention made by a DAP inventor and two sole VA inventors, University would direct from *** Research Share, *** to the appropriate University research program and *** to the
VA for its appropriate research program. 

  

	 	4.3	Net Revenues. University agrees to pay to VA an amount equivalent to *** of the Pooled Amount for each UC Site less payments made by University to VA for previous Fiscal Years.
University’s obligation to make payments to VA shall commence from the date that the Pooled Amount calculation is positive for a UC Site. Such payments are payable in annual installments and are due no later than January 31 for Pooled Amount
calculation made for the prior Fiscal Year. 

  

	 	4.4	All payments to VA, required under this Agreement shall be in U.S. Dollars and shall be made by University by check or bank draft drawn on United States banks and shall be payable,
as appropriate, to the “Department of Veterans Affairs (royalty).” All such payments shall be sent to the following address: 

  
 Department of Veterans Affairs 
 Technology
Transfer Financial Management Office (12TT) 
 810 Vermont Avenue NW 
 Washington, D.C. 20420 

	***	Material has been omitted pursuant to a request for confidential treatment. 

  

 5 

 The payment under Section 4.3 will be accompanied with an itemized accounting of performance of each
individual Subject Invention. 
  

	5.	RECORDS AND REPORTS 

  

	 	5.1	University shall keep complete, true, and accurate accounts of all Expenses and of all Gross Revenues received by it under each License Agreement and shall permit VA or VA’s
designated agent to examine its books and records in order to verify the payments due or owed under this Agreement. 

  

	 	5.2	University shall submit to VA at the address identified in Article 8 a semi-annual report, not later than January 31 covering the period through the prior June 30 and not later than
April 30 covering the period through the prior December 31, setting forth the status of all patent prosecution, commercial development, and licensing activity concerning Subject Invention(s), and upon request of the VA, copies of patents issued and,
in confidence, License Agreements executed during that period. 

  

	 	5.3	The report required under Section 5.2 shall also be made within sixty (60) days of the termination of this Agreement. 

  

	6.	PATENT INFRINGEMENT 

  

	 	6.1	If the administrators responsible for this Agreement at VA or University learns of the substantial infringement of any Subject Invention, then the party who learns of the
infringement will promptly call attention to the infringement in writing to the other party and provide the other party with reasonable evidence of the infringement. Neither party will notify a third party of infringement without first obtaining
written consent of the other party, which consent will not be unreasonably withheld. University, in cooperation with VA, will use its best efforts to terminate the infringement without litigation. If the efforts of the parties are not successful in
abating the infringement within 90 days after the infringement was formally brought to the attention of the parties, then either party will have the right to elect to: 

  

	 	6.1.1 	commence suit on its own account; 

  

	 	6.1.2 	permit an exclusive Licensee to bring suit separately, but only if University or VA elects not to bring suit; 

  

	 	6.1.3 	join with the other party or an exclusive Licensee in the suit; or 

  

	 	6.1.4 	refuse to participate in the suit; 

  
 and each party will give written notice of its election to the other party within 10 days after the 90-day period. University may permit an exclusive
Licensee to bring suit on its own account, either by formal notice or by failure to act within the period, but only if University or VA elects not to commence suit or join each other in any suit. 
  

 6 

	 	6.2	Such legal action as is decided upon will be at the expense of the party on account of whom suit is brought and all recoveries recovered thereby will belong to such party, provided,
however, that legal action brought by VA, University, and/or an exclusive Licensee, and participated in by the parties bringing suit will be at the expense of such parties, and all recoveries will be allocated in the following order:

  

	 	6.2.1 	to each party reimbursement in equal amounts of the attorney’s costs, fees, and other related expenses to the extent each party paid for such costs, fees, and expenses until
all such costs, fees, and expenses are consumed for each party; and 

  

	 	6.2.2 	any remaining amount shared by them in proportion to the share of expenses paid by each party. 

  

	 	6.3	Each party will cooperate with the other in litigation proceedings instituted under this Agreement but at the expense of the party on account of whom suit is brought. This
litigation (including settlement) will be controlled by the party bringing the suit, except that University will control the suit if brought jointly. Either party may be represented at its sole expense by counsel of its choice in any suit brought by
the other party or an exclusive Licensee. VA’s agreement in this paragraph is subject to U.S. Department of Justice approval on a case-by-case basis. 

  

	7.	TERM AND TERMINATION 

  

	 	7.1	Term. This Agreement is effective when signed by both parties and shall extend until the expiration of the last-to-expire of the License Agreements or patents covering a Subject
Invention included under this Agreement, whichever is later, unless otherwise terminated by operation of law or by acts of the parties in accordance with the terms of this Agreement. 

  

	 	7.2	Termination by Mutual Consent. University and VA may elect to terminate this Agreement, or portions thereof, at any time by mutual consent in writing. In such event, any outstanding
commitments to third parties through License Agreements, options thereto, or research agreements concerning any Subject Invention(s) or future inventions that would be Subject Inventions under this Agreement that were entered into by University or
were reliant on this Agreement prior to the effective termination date shall survive this Agreement. 

  

	 	7.3	Termination by Unilateral Action. 

  

	 	7.3.1 	Written Notice. Either Party may unilaterally terminate this entire Agreement at any time by giving the other Party prior written notice, but not less than six (6) months prior to
the desired termination date. 

  

	 	7.3.2 	 Commitments. In such event, any outstanding commitments to third parties through License Agreements, options thereto, or research agreements concerning any Subject
Invention(s) or future inventions that would be Subject Inventions under this Agreement that were entered into by University or were reliant on this 

  

 7 

	 	 
Agreement prior to the effective termination date shall survive this Agreement. All uncancelable obligations shall be included within Expenses.

  

	 	7.4	Termination of License Agreement by VA. The VA may terminate a License Agreement if it is determined by VA that: 

  

	 	7.4.1 	University or any of its Licensees substantially fail to meet the material obligations set forth in the License Agreement: or 

  

	 	7.4.2 	The VA determines that such action is necessary to meet requirements for public use specified by federal regulations issued after the date of this Agreement and such requirements
are not reasonably satisfied by University or any Licensees; or 

  

	 	7.4.3 	University or any Licensees have willfully made a material false statement of, or willfully omitted, a material fact in any report required by this Agreement: or

  

	 	7.4.4 	University or any Licensees commit a substantial breach of covenant or agreement contained in the License Agreement; or 

  

	 	7.4.5 	University or any Licensees materially defaults in making any payment or report required by this Agreement or a License Agreement; or 

  

	 	7.4.6 	University or any Licensees is adjudged as bankrupt or has its assets placed in the hands of the receiver or makes any assignment or other accommodation for the benefit of
creditors; or 

  

	 	7.4.7 	University is held by a court of competent jurisdiction, without taking a further appeal, to have misused any patent rights covering a Subject Invention. 

 

	 	7.5	Prior to any termination of the License Agreement, VA shall furnish University and any Licensee of record a written notice of intention to terminate, and University and any notified
Licensee shall be allowed 30 days after the date of such notice to remedy any breach or default of any covenant or agreement of the License Agreement or to show cause why the License Agreement should not be terminated. 

  

	 	7.6	The word termination’ and cognate words, such as ‘term’ and ‘terminate,’ used in this Article 7 and elsewhere in this Agreement are to be read, except where
the contrary is specifically indicated, as omitting from their effect the following rights and obligations all of which survive any termination to the degree necessary to permit their complete fulfillment or discharge; 

  

	 	7.6.1 	University’s obligation to supply a terminal report as specified in Section 5.3 of this Agreement. 

  

	 	7.6.2 	VA’s right to receive or recover and University’s obligation to share Net Revenues or accruable for payment at the time of any termination as specified in Article 4 of
this Agreement. 

  

	 	7.6.3 	University’s obligation to maintain records and VA’s right to conduct a final audit pursuant to Section 5.1 of this Agreement. 

  

 8 

	 	7.6.4	Sublicenses, releases, and agreements of non-assertion running in favor of Licensees prior to any termination and on which royalties shall have been paid. 

 

	 	7.6.5	Any cause of action or claim VA accrued or to accrue, because of any breach or default by University. 

  

	 	7.7	In the event the termination of this Agreement or conversion of this Agreement, any Licensee of record granted pursuant to this Agreement may, at Licensee’s option, be
converted to a license directly between Licensee and VA. 

  

	 	7.8	After effective termination, each party may separately license its interests in Subject Inventions according to its own policy. Apart from specific obligations of the parties under
this Agreement accrued prior to termination, the parties will have no further rights or obligations under this Agreement after such termination. 

  

	8.	NOTICES 

  
 All notices required or permitted by this Agreement to be given to the parties thereto shall be deemed to have been properly given if delivered in writing, in person or mailed by prepaid, first class, registered or
certified mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed to the other Party. Notices shall be considered timely if such notices are received on or before the established deadline date or sent on
or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.
S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing. 
  
 Notices shall be sent to the mailing address below, or alternative address(es) for individual Subject Inventions as identified in writing by the VA
Director, Technology Transfer Program or by the University Executive Director, Research Administration and Technology Transfer. 
  

			
	 To VA:
	  	 Director (122)
 Technology Transfer Program

Office of Research and Development
 U.S. Department of Veterans
Affairs
 810 Vermont Avenue N.W.
 Washington, D.C.
20420

		
	 To University:
	  	 The Regents of the University of California
 Office of
the President
 Office of Technology Transfer (OTT)
 1111 Franklin
Street, 5th Floor
 Oakland, California 94607-5200
 Attention:
Executive Director,
 Research Administration and Technology Transfer

  

 9 

	9.	GOVERNING LAWS, SETTLING DISPUTES 

  

	 	9.1	This Agreement shall be construed in accordance with U.S. Federal law and the law of the State of California when not in conflict with U.S. Federal law. Federal law and regulations
will preempt any conflicting or inconsistent provisions in this Agreement. University shall have all defenses available to it under California law. 

  

	 	9.2	Any controversy or any disputed claim by either party against the other arising under or related to this Agreement shall be submitted jointly to University, Executive Director of
Research Administration and Technology Transfer, and to the VA, Director, Technology Transfer Program, Office of Research and Development. University and VA will be free after written decisions are issued by those officials to pursue any and all
administrative and/or judicial remedies that may be available. 

  

	10.	MISCELLANEOUS 

  

	 	10.1	The Agreement or anything related thereto shall not be construed to confer on any person any immunity from or defenses under the antitrust laws or from a charge of patent misuse,
and the acquisition and use of rights pursuant to this Agreement shall not be immunized from the operation of state or Federal law by reason of the source of the grant. 

  

	 	10.2	It is agreed that no waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent
and/or similar breach or default. 

  

	 	10.3	This Agreement is binding upon and shall inure to the benefit of the parties hereto, their successors or assigns, but this Agreement may not be assigned by either party without the
prior written consent of the other party. 

  

	 	10.4	This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of University or VA other than Subject Inventions
regardless of whether such patents are dominant or subordinate to Subject Inventions. 

  

	 	10.5	Any modification to this Agreement must be in writing and agreed to by both parties. 

  

	 	10.6	It is understood and agreed by University and VA that this Agreement constitutes the entire agreement, both written and oral, between the parties, and that all prior agreements
respecting the subject matter hereof, either written or oral, express or implied, shall be abrogated, canceled, and are null and void and of no effect. 

  

	 	10.7	Use of Name. Neither party may use the name of the other party in any way for advertising or publicity without the express written consent of the other party, provided, however,
that while University may not allow a Licensee to use the name of VA for advertising or publicity, it does have the right to use the name of VA in connection with negotiating a License Agreement or sublicense agreement and where required by law.

  

 10 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives as
follows: 
  

									
	 U.S. DEPARTMENT OF VETERANS AFFAIRS
	 	 	 	 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

			
	 EXECUTED ON 5/19/00 BY
 James F. Burris, M.D. for:
	 	 	 	EXECUTED ON 5/18/ BY:
					
	By:	 	/s/                    	 	 	 	By:	 	/s/                    
	 	 	
	 	 	 	 	 	

	 Name:
	 	John R. Feussner, M.D.	 	 	 	 Name:
	 	Alan B. Bennett
	 Title:
	 	Chief Research and Development Officer	 	 	 	 Title:
	 	 Executive Director,
 Research Administration and
 Technology Transfer

	 Date:
	 	 	 	 	 	 Date:
	 	 
	 	 	
	 	 	 	 	 	

  

 11 

 EXHIBIT C 
  
 The Regents’ rights in the following: 
 *** 

	***	Material has been omitted pursuant to a request for confidential treatment. 

  

 EXHIBIT D 
  

			
	PROSECUTION COSTS
		
	 UC Case Nos.

	  	Costs

	 1999-238
	  	***
	 1992-283
	  	***
	 1992-383
	  	***
	 1996-036
	  	***
	 1997-128
	  	***
	 2000-343
	  	***
	 2000-470
	  	***
	 2001-096
	  	***
	 2001-278
	  	***
	 2001-399
	  	***
	 2001-504
	  	***
	 2001-505
	  	***
	 	  	

	 TOTAL:
	  	***
	 	  	

	***	Material has been omitted pursuant to a request for confidential treatment.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]